SK6842003A3 - Aryl ether substituted imidazoquinolines - Google Patents
Aryl ether substituted imidazoquinolines Download PDFInfo
- Publication number
- SK6842003A3 SK6842003A3 SK684-2003A SK6842003A SK6842003A3 SK 6842003 A3 SK6842003 A3 SK 6842003A3 SK 6842003 A SK6842003 A SK 6842003A SK 6842003 A3 SK6842003 A3 SK 6842003A3
- Authority
- SK
- Slovakia
- Prior art keywords
- alkyl
- aryl
- imidazo
- alkenyl
- compound
- Prior art date
Links
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 title description 5
- 125000005013 aryl ether group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 170
- 125000003118 aryl group Chemical group 0.000 claims abstract description 75
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 48
- 102000004127 Cytokines Human genes 0.000 claims abstract description 37
- 108090000695 Cytokines Proteins 0.000 claims abstract description 37
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 21
- 201000010099 disease Diseases 0.000 claims abstract description 20
- 230000003612 virological effect Effects 0.000 claims abstract description 11
- 230000001613 neoplastic effect Effects 0.000 claims abstract description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 130
- 229910052799 carbon Inorganic materials 0.000 claims description 117
- 125000000217 alkyl group Chemical group 0.000 claims description 102
- 238000000034 method Methods 0.000 claims description 93
- 150000003839 salts Chemical class 0.000 claims description 68
- 229910052736 halogen Inorganic materials 0.000 claims description 41
- 125000001424 substituent group Chemical group 0.000 claims description 32
- 241001465754 Metazoa Species 0.000 claims description 31
- 150000002367 halogens Chemical class 0.000 claims description 26
- 125000003545 alkoxy group Chemical group 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 20
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 20
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 19
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
- 125000001997 phenyl group Chemical class [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 102000006992 Interferon-alpha Human genes 0.000 claims description 9
- 108010047761 Interferon-alpha Proteins 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 8
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical group CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 125000005741 alkyl alkenyl group Chemical group 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract description 71
- 239000000203 mixture Substances 0.000 abstract description 55
- 230000028993 immune response Effects 0.000 abstract description 12
- 238000011282 treatment Methods 0.000 abstract description 12
- GCGNWZMOENODOJ-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-imidazo[4,5-h]quinoline Chemical class C1C=C2C=CC=NC2=C2C1NCN2 GCGNWZMOENODOJ-UHFFFAOYSA-N 0.000 abstract description 6
- 239000003607 modifier Substances 0.000 abstract description 4
- SQQXRXKYTKFFSM-UHFFFAOYSA-N chembl1992147 Chemical compound OC1=C(OC)C(OC)=CC=C1C1=C(C)C(C(O)=O)=NC(C=2N=C3C4=NC(C)(C)N=C4C(OC)=C(O)C3=CC=2)=C1N SQQXRXKYTKFFSM-UHFFFAOYSA-N 0.000 abstract 1
- 229940124669 imidazoquinoline Drugs 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 408
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 354
- 238000006243 chemical reaction Methods 0.000 description 227
- 239000007787 solid Substances 0.000 description 150
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 137
- 229910052757 nitrogen Inorganic materials 0.000 description 112
- -1 4-amino-1H-imidazo [4,5-c] quinolin-1-yl Chemical group 0.000 description 104
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 93
- 239000000243 solution Substances 0.000 description 93
- 239000011541 reaction mixture Substances 0.000 description 81
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 76
- 238000004458 analytical method Methods 0.000 description 73
- 238000007429 general method Methods 0.000 description 68
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 68
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 66
- 239000003921 oil Substances 0.000 description 62
- 235000019198 oils Nutrition 0.000 description 62
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 61
- 239000000047 product Substances 0.000 description 56
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 55
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 53
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 51
- 239000000463 material Substances 0.000 description 50
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 48
- SORQIYFSJAWBNQ-UHFFFAOYSA-N 1-iodo-2-propan-2-ylbenzene Chemical compound CC(C)C1=CC=CC=C1I SORQIYFSJAWBNQ-UHFFFAOYSA-N 0.000 description 47
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 40
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 38
- 239000002904 solvent Substances 0.000 description 38
- 239000012458 free base Substances 0.000 description 32
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 31
- HQBUPOAKJGJGCD-UHFFFAOYSA-N 3h-imidazo[4,5-c]quinolin-4-amine Chemical class NC1=NC2=CC=CC=C2C2=C1N=CN2 HQBUPOAKJGJGCD-UHFFFAOYSA-N 0.000 description 30
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 30
- 235000019341 magnesium sulphate Nutrition 0.000 description 30
- 238000000746 purification Methods 0.000 description 30
- 238000005259 measurement Methods 0.000 description 27
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 26
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 26
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 25
- 238000001914 filtration Methods 0.000 description 24
- 239000002244 precipitate Substances 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 238000001953 recrystallisation Methods 0.000 description 22
- 239000000741 silica gel Substances 0.000 description 22
- 229910002027 silica gel Inorganic materials 0.000 description 22
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 21
- 239000012267 brine Substances 0.000 description 21
- 239000003054 catalyst Substances 0.000 description 21
- 150000004820 halides Chemical class 0.000 description 21
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 21
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 20
- 239000000706 filtrate Substances 0.000 description 20
- 238000003818 flash chromatography Methods 0.000 description 20
- 238000003756 stirring Methods 0.000 description 20
- 238000004809 thin layer chromatography Methods 0.000 description 20
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 19
- 239000012299 nitrogen atmosphere Substances 0.000 description 18
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 18
- 238000004440 column chromatography Methods 0.000 description 17
- 238000007796 conventional method Methods 0.000 description 17
- 239000000843 powder Substances 0.000 description 17
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 16
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 16
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 16
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 16
- 150000004703 alkoxides Chemical class 0.000 description 16
- 238000011894 semi-preparative HPLC Methods 0.000 description 16
- 239000012312 sodium hydride Substances 0.000 description 16
- 229910000104 sodium hydride Inorganic materials 0.000 description 16
- 238000010438 heat treatment Methods 0.000 description 15
- GRNOZCCBOFGDCL-UHFFFAOYSA-N 2,2,2-trichloroacetyl isocyanate Chemical compound ClC(Cl)(Cl)C(=O)N=C=O GRNOZCCBOFGDCL-UHFFFAOYSA-N 0.000 description 14
- 125000005977 3-phenylpropyloxy group Chemical group 0.000 description 14
- FQYRLEXKXQRZDH-UHFFFAOYSA-N 4-aminoquinoline Chemical compound C1=CC=C2C(N)=CC=NC2=C1 FQYRLEXKXQRZDH-UHFFFAOYSA-N 0.000 description 14
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 14
- 239000012223 aqueous fraction Substances 0.000 description 14
- OVPPDFOKBBTFHT-UHFFFAOYSA-N 4-n-(2-phenoxyethyl)quinoline-3,4-diamine Chemical compound NC1=CN=C2C=CC=CC2=C1NCCOC1=CC=CC=C1 OVPPDFOKBBTFHT-UHFFFAOYSA-N 0.000 description 13
- 150000001412 amines Chemical class 0.000 description 13
- 230000006698 induction Effects 0.000 description 13
- 239000010410 layer Substances 0.000 description 13
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 13
- 239000003039 volatile agent Substances 0.000 description 13
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 12
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 11
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 11
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 11
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 11
- 108010050904 Interferons Proteins 0.000 description 11
- 102000014150 Interferons Human genes 0.000 description 11
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
- 239000000908 ammonium hydroxide Substances 0.000 description 11
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 11
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 11
- 229940079322 interferon Drugs 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- 235000017557 sodium bicarbonate Nutrition 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzenecarbonitrile Natural products N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 239000007858 starting material Substances 0.000 description 10
- 238000010189 synthetic method Methods 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- KXHPPCXNWTUNSB-UHFFFAOYSA-M benzyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC1=CC=CC=C1 KXHPPCXNWTUNSB-UHFFFAOYSA-M 0.000 description 9
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 9
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 9
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 9
- 239000000543 intermediate Substances 0.000 description 9
- 239000002480 mineral oil Substances 0.000 description 9
- 235000010446 mineral oil Nutrition 0.000 description 9
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 9
- 125000000714 pyrimidinyl group Chemical group 0.000 description 9
- 238000010898 silica gel chromatography Methods 0.000 description 9
- 125000006516 2-(benzyloxy)ethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- YCOXTKKNXUZSKD-UHFFFAOYSA-N as-o-xylenol Natural products CC1=CC=C(O)C=C1C YCOXTKKNXUZSKD-UHFFFAOYSA-N 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- SNHMUERNLJLMHN-UHFFFAOYSA-N iodobenzene Chemical compound IC1=CC=CC=C1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
- KDRFSAWHTAWZAC-UHFFFAOYSA-N 1-(2-prop-2-ynoxyethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound NC1=NC2=CC=CC=C2C2=C1N=CN2CCOCC#C KDRFSAWHTAWZAC-UHFFFAOYSA-N 0.000 description 7
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 7
- 150000001204 N-oxides Chemical class 0.000 description 7
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 7
- 239000012467 final product Substances 0.000 description 7
- 125000001072 heteroaryl group Chemical group 0.000 description 7
- 125000000623 heterocyclic group Chemical group 0.000 description 7
- 210000005260 human cell Anatomy 0.000 description 7
- 239000012948 isocyanate Substances 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 7
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 7
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 7
- VCNWVTNERDDKEA-UHFFFAOYSA-N 1-imidazo[4,5-c]quinolin-1-yloxyimidazo[4,5-c]quinoline Chemical compound C1=NC2=CN=C3C=CC=CC3=C2N1ON1C2=C3C=CC=CC3=NC=C2N=C1 VCNWVTNERDDKEA-UHFFFAOYSA-N 0.000 description 6
- ITIRVXDSMXFTPW-UHFFFAOYSA-N 1H-imidazo[4,5-c]quinoline Chemical group C1=CC=CC2=C(NC=N3)C3=CN=C21 ITIRVXDSMXFTPW-UHFFFAOYSA-N 0.000 description 6
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 239000005711 Benzoic acid Substances 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- FHRRJZZGSJXPRQ-UHFFFAOYSA-N benzyl phenylmethoxycarbonyl carbonate Chemical compound C=1C=CC=CC=1COC(=O)OC(=O)OCC1=CC=CC=C1 FHRRJZZGSJXPRQ-UHFFFAOYSA-N 0.000 description 6
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 6
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 6
- 150000002513 isocyanates Chemical class 0.000 description 6
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000001665 trituration Methods 0.000 description 6
- 238000003828 vacuum filtration Methods 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- 235000010233 benzoic acid Nutrition 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 239000012442 inert solvent Substances 0.000 description 5
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000002604 ultrasonography Methods 0.000 description 5
- SKOBGLOJJGVOSV-SNVBAGLBSA-N (2r)-2-imidazo[4,5-c]quinolin-1-ylbutan-1-ol Chemical compound C1=CC=CC2=C3N([C@@H](CO)CC)C=NC3=CN=C21 SKOBGLOJJGVOSV-SNVBAGLBSA-N 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- DMQAXDOKKRWQEE-UHFFFAOYSA-N 1-(2H-quinolin-1-yloxy)-2H-quinoline Chemical compound N1(CC=CC2=CC=CC=C12)ON1CC=CC2=CC=CC=C12 DMQAXDOKKRWQEE-UHFFFAOYSA-N 0.000 description 4
- JWRNUPCIPGBNGE-UHFFFAOYSA-N 2-[2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]ethanol Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CCO)C3=CN=C21 JWRNUPCIPGBNGE-UHFFFAOYSA-N 0.000 description 4
- FZZMTSNZRBFGGU-UHFFFAOYSA-N 2-chloro-7-fluoroquinazolin-4-amine Chemical compound FC1=CC=C2C(N)=NC(Cl)=NC2=C1 FZZMTSNZRBFGGU-UHFFFAOYSA-N 0.000 description 4
- HKIWBOKRKRFJNV-UHFFFAOYSA-N 2-imidazo[4,5-c]quinolin-1-ylethanol Chemical compound C1=CC=CC2=C3N(CCO)C=NC3=CN=C21 HKIWBOKRKRFJNV-UHFFFAOYSA-N 0.000 description 4
- SHKUAAUCZDOPDI-UHFFFAOYSA-N 4-chloro-3h-imidazo[4,5-c]quinoline Chemical compound ClC1=NC2=CC=CC=C2C2=C1N=CN2 SHKUAAUCZDOPDI-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 230000003301 hydrolyzing effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 4
- 125000004549 quinolin-4-yl group Chemical group N1=CC=C(C2=CC=CC=C12)* 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 3
- QUJSHZMLFMCARS-UHFFFAOYSA-N 1-hydroxyimidazo[4,5-c]quinoline Chemical compound C1=CC=CC2=C3N(O)C=NC3=CN=C21 QUJSHZMLFMCARS-UHFFFAOYSA-N 0.000 description 3
- WGIYTEIRCZCJHL-UHFFFAOYSA-N 2-(2-methoxyethyl)-1-[2-(3-phenylprop-2-ynoxy)ethyl]imidazo[4,5-c]quinoline Chemical compound COCCC1=NC2=CN=C3C=CC=CC3=C2N1CCOCC#CC1=CC=CC=C1 WGIYTEIRCZCJHL-UHFFFAOYSA-N 0.000 description 3
- CTBSUXMGJGWLDE-UHFFFAOYSA-N 2-(4-aminoimidazo[4,5-c]quinolin-1-yl)butan-1-ol Chemical compound C1=CC=CC2=C3N(C(CO)CC)C=NC3=C(N)N=C21 CTBSUXMGJGWLDE-UHFFFAOYSA-N 0.000 description 3
- GWFWDZPTXFFCQI-UHFFFAOYSA-N 2-octyl-1-[2-(3-phenylprop-2-ynoxy)ethyl]imidazo[4,5-c]quinoline Chemical compound CCCCCCCCC1=NC2=CN=C3C=CC=CC3=C2N1CCOCC#CC1=CC=CC=C1 GWFWDZPTXFFCQI-UHFFFAOYSA-N 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
- ZRFUZDDJSQVQBY-UHFFFAOYSA-N 4-chloro-3-nitroquinoline Chemical compound C1=CC=CC2=C(Cl)C([N+](=O)[O-])=CN=C21 ZRFUZDDJSQVQBY-UHFFFAOYSA-N 0.000 description 3
- YHQPYMQQMBVULM-UHFFFAOYSA-N 6,7,8,9-tetrahydro-3h-imidazo[4,5-c]quinolin-4-amine Chemical compound C1CCCC2=C1N=C(N)C1=C2NC=N1 YHQPYMQQMBVULM-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 description 3
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 3
- 239000012455 biphasic mixture Substances 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 3
- 125000004663 dialkyl amino group Chemical group 0.000 description 3
- ODCCJTMPMUFERV-UHFFFAOYSA-N ditert-butyl carbonate Chemical group CC(C)(C)OC(=O)OC(C)(C)C ODCCJTMPMUFERV-UHFFFAOYSA-N 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 125000004993 haloalkoxycarbonyl group Chemical group 0.000 description 3
- 125000004692 haloalkylcarbonyl group Chemical group 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 229940121354 immunomodulator Drugs 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229940047122 interleukins Drugs 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 230000000051 modifying effect Effects 0.000 description 3
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 3
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 3
- 239000003444 phase transfer catalyst Substances 0.000 description 3
- 229910003446 platinum oxide Inorganic materials 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 125000003107 substituted aryl group Chemical group 0.000 description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 3
- 229910052723 transition metal Inorganic materials 0.000 description 3
- 150000003624 transition metals Chemical class 0.000 description 3
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- HRATYRRGCLIWCL-SECBINFHSA-N (2R)-3-(4-aminoimidazo[4,5-c]quinolin-1-yl)-2-methylpropan-1-ol Chemical compound NC1=NC=2C=CC=CC=2C2=C1N=CN2C[C@H](CO)C HRATYRRGCLIWCL-SECBINFHSA-N 0.000 description 2
- XQKXTFRTKLSYAE-SECBINFHSA-N (2R)-3-(4-chloroimidazo[4,5-c]quinolin-1-yl)-2-methylpropan-1-ol Chemical compound C[C@H](CN1C=NC2=C1C3=CC=CC=C3N=C2Cl)CO XQKXTFRTKLSYAE-SECBINFHSA-N 0.000 description 2
- OENOQVGYHBVELS-SECBINFHSA-N (2r)-2-[(3-aminoquinolin-4-yl)amino]butan-1-ol Chemical compound C1=CC=C2C(N[C@@H](CO)CC)=C(N)C=NC2=C1 OENOQVGYHBVELS-SECBINFHSA-N 0.000 description 2
- OARIKEKDLUAWRB-SECBINFHSA-N (2r)-2-[(3-nitroquinolin-4-yl)amino]butan-1-ol Chemical compound C1=CC=C2C(N[C@@H](CO)CC)=C([N+]([O-])=O)C=NC2=C1 OARIKEKDLUAWRB-SECBINFHSA-N 0.000 description 2
- ZIIJWXPUTIQWEO-MRVPVSSYSA-N (2r)-3-[(2-chloro-3-nitroquinolin-4-yl)amino]-2-methylpropan-1-ol Chemical compound C1=CC=C2C(NC[C@H](CO)C)=C([N+]([O-])=O)C(Cl)=NC2=C1 ZIIJWXPUTIQWEO-MRVPVSSYSA-N 0.000 description 2
- RFOZIVIKPJVQOA-UHFFFAOYSA-N 1-(2-phenoxyethyl)-2-(phenoxymethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound C=1C=CC=CC=1OCC1=NC=2C(N)=NC3=CC=CC=C3C=2N1CCOC1=CC=CC=C1 RFOZIVIKPJVQOA-UHFFFAOYSA-N 0.000 description 2
- HOTMJHUAOUWOPN-UHFFFAOYSA-N 1-(2-prop-2-ynoxyethyl)imidazo[4,5-c]quinoline Chemical compound C1=CC=CC2=C3N(CCOCC#C)C=NC3=CN=C21 HOTMJHUAOUWOPN-UHFFFAOYSA-N 0.000 description 2
- FTJFSOZOTSXKRT-UHFFFAOYSA-N 1-[2-(3-phenylprop-2-ynoxy)ethyl]imidazo[4,5-c]quinolin-4-amine Chemical compound C1=NC=2C(N)=NC3=CC=CC=C3C=2N1CCOCC#CC1=CC=CC=C1 FTJFSOZOTSXKRT-UHFFFAOYSA-N 0.000 description 2
- ZKSQQSIYJOMHBZ-UHFFFAOYSA-N 1-[2-(3-phenylprop-2-ynoxy)ethyl]imidazo[4,5-c]quinolin-4-amine;hydrochloride Chemical compound Cl.C1=NC=2C(N)=NC3=CC=CC=C3C=2N1CCOCC#CC1=CC=CC=C1 ZKSQQSIYJOMHBZ-UHFFFAOYSA-N 0.000 description 2
- SGFRUHSAHWBOMW-UHFFFAOYSA-N 1-[2-[3-(2-aminophenyl)propoxy]ethyl]imidazo[4,5-c]quinolin-4-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NC1=CC=CC=C1CCCOCCN1C2=C3C=CC=CC3=NC(N)=C2N=C1 SGFRUHSAHWBOMW-UHFFFAOYSA-N 0.000 description 2
- UODQYYMUKWUSCP-UHFFFAOYSA-N 1-[2-[3-[3-(dimethylamino)phenyl]propoxy]ethyl]imidazo[4,5-c]quinolin-4-amine;dihydrochloride Chemical compound Cl.Cl.CN(C)C1=CC=CC(CCCOCCN2C3=C4C=CC=CC4=NC(N)=C3N=C2)=C1 UODQYYMUKWUSCP-UHFFFAOYSA-N 0.000 description 2
- UFPIGVZODKVOAR-UHFFFAOYSA-N 2,2,2-trichloro-n-(3h-imidazo[4,5-c]quinolin-4-yl)acetamide Chemical compound ClC(Cl)(Cl)C(=O)NC1=NC2=CC=CC=C2C2=C1N=CN2 UFPIGVZODKVOAR-UHFFFAOYSA-N 0.000 description 2
- SGRJPOFGYWCKRN-UHFFFAOYSA-N 2,2,2-trichloro-n-[2-methyl-1-(2-phenylmethoxyethyl)imidazo[4,5-c]quinolin-4-yl]acetamide Chemical compound CC1=NC2=C(NC(=O)C(Cl)(Cl)Cl)N=C3C=CC=CC3=C2N1CCOCC1=CC=CC=C1 SGRJPOFGYWCKRN-UHFFFAOYSA-N 0.000 description 2
- RSFJVCHKGRUCIC-UHFFFAOYSA-N 2,4-dichloro-3-nitroquinoline Chemical compound C1=CC=CC2=C(Cl)C([N+](=O)[O-])=C(Cl)N=C21 RSFJVCHKGRUCIC-UHFFFAOYSA-N 0.000 description 2
- YGPGODVPZRNJAL-UHFFFAOYSA-N 2-(2-cyclopentylethyl)-1-(2-phenoxyethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound C1CCCC1CCC1=NC=2C(N)=NC3=CC=CC=C3C=2N1CCOC1=CC=CC=C1 YGPGODVPZRNJAL-UHFFFAOYSA-N 0.000 description 2
- NWHJOTMHPVDARX-UHFFFAOYSA-N 2-(2-methoxyethyl)-1-(2-prop-2-ynoxyethyl)imidazo[4,5-c]quinoline Chemical compound C1=CC=CC2=C(N(C(CCOC)=N3)CCOCC#C)C3=CN=C21 NWHJOTMHPVDARX-UHFFFAOYSA-N 0.000 description 2
- YTWIUBXOJMBNSM-UHFFFAOYSA-N 2-(2-methoxyethyl)-1-[2-(3-phenylpropoxy)ethyl]imidazo[4,5-c]quinolin-4-amine Chemical compound COCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCOCCCC1=CC=CC=C1 YTWIUBXOJMBNSM-UHFFFAOYSA-N 0.000 description 2
- MAZJGZWFZKSCNJ-UHFFFAOYSA-N 2-(2-methoxyethyl)-1-[2-(3-phenylpropoxy)ethyl]imidazo[4,5-c]quinoline Chemical compound COCCC1=NC2=CN=C3C=CC=CC3=C2N1CCOCCCC1=CC=CC=C1 MAZJGZWFZKSCNJ-UHFFFAOYSA-N 0.000 description 2
- KMUCWHATANQQNF-UHFFFAOYSA-N 2-(2-methyl-5-oxidoimidazo[4,5-c]quinolin-5-ium-1-yl)ethyl acetate Chemical compound C1=CC=CC2=C3N(CCOC(=O)C)C(C)=NC3=C[N+]([O-])=C21 KMUCWHATANQQNF-UHFFFAOYSA-N 0.000 description 2
- MMJGOJJUJXHOHW-UHFFFAOYSA-N 2-(2-methylpropyl)-1-(2-phenoxyethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound CC(C)CC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCOC1=CC=CC=C1 MMJGOJJUJXHOHW-UHFFFAOYSA-N 0.000 description 2
- JBMPYXYQJQFTEM-UHFFFAOYSA-N 2-(4-amino-2-methylimidazo[4,5-c]quinolin-1-yl)ethyl acetate Chemical compound C1=CC=CC2=C3N(CCOC(=O)C)C(C)=NC3=C(N)N=C21 JBMPYXYQJQFTEM-UHFFFAOYSA-N 0.000 description 2
- MOBMMDLVPMBOIC-UHFFFAOYSA-N 2-(4-chloro-2-methylimidazo[4,5-c]quinolin-1-yl)ethanol Chemical compound C1=CC=CC2=C(N(C(C)=N3)CCO)C3=C(Cl)N=C21 MOBMMDLVPMBOIC-UHFFFAOYSA-N 0.000 description 2
- RYNWGMWQWSELIC-UHFFFAOYSA-N 2-(cyclopropylmethyl)-1-(2-phenoxyethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound C1CC1CC1=NC=2C(N)=NC3=CC=CC=C3C=2N1CCOC1=CC=CC=C1 RYNWGMWQWSELIC-UHFFFAOYSA-N 0.000 description 2
- PHSFDHHFZCYJCM-UHFFFAOYSA-N 2-(ethoxymethyl)-1-(2-phenylmethoxyethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCOCC1=CC=CC=C1 PHSFDHHFZCYJCM-UHFFFAOYSA-N 0.000 description 2
- QLEMGCFYAKWGPC-UHFFFAOYSA-N 2-(ethoxymethyl)-1-[2-(3-phenylmethoxypropoxy)ethyl]imidazo[4,5-c]quinoline Chemical compound CCOCC1=NC2=CN=C3C=CC=CC3=C2N1CCOCCCOCC1=CC=CC=C1 QLEMGCFYAKWGPC-UHFFFAOYSA-N 0.000 description 2
- AHJQGGHQKUAZKX-UHFFFAOYSA-N 2-(ethoxymethyl)-1-[2-(3-phenylprop-2-ynoxy)ethyl]imidazo[4,5-c]quinolin-4-amine Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCOCC#CC1=CC=CC=C1 AHJQGGHQKUAZKX-UHFFFAOYSA-N 0.000 description 2
- VYZDWCSXBGWWMO-UHFFFAOYSA-N 2-(ethoxymethyl)-1-[2-(3-phenylprop-2-ynoxy)ethyl]imidazo[4,5-c]quinoline Chemical compound CCOCC1=NC2=CN=C3C=CC=CC3=C2N1CCOCC#CC1=CC=CC=C1 VYZDWCSXBGWWMO-UHFFFAOYSA-N 0.000 description 2
- TYAOCRVWDXVFEX-UHFFFAOYSA-N 2-(ethoxymethyl)-1-[2-[6-(4-phenylbutoxy)hexoxy]ethyl]imidazo[4,5-c]quinolin-4-amine Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCOCCCCCCOCCCCC1=CC=CC=C1 TYAOCRVWDXVFEX-UHFFFAOYSA-N 0.000 description 2
- KOABOSCMHUTQRB-UHFFFAOYSA-N 2-[(4-methoxyphenyl)methyl]-1-(2-phenoxyethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC(OC)=CC=C1CC1=NC2=C(N)N=C(C=CC=C3)C3=C2N1CCOC1=CC=CC=C1 KOABOSCMHUTQRB-UHFFFAOYSA-N 0.000 description 2
- DZRDHDZHHLBVGS-UHFFFAOYSA-N 2-[2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]ethanol Chemical compound C1=CC=CC2=C(N(C(CCOC)=N3)CCO)C3=CN=C21 DZRDHDZHHLBVGS-UHFFFAOYSA-N 0.000 description 2
- ZGUWHIGQDIKPNE-UHFFFAOYSA-N 2-butyl-1-(2-phenoxyethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCOC1=CC=CC=C1 ZGUWHIGQDIKPNE-UHFFFAOYSA-N 0.000 description 2
- MBPUDPUZEMFZSW-UHFFFAOYSA-N 2-butyl-1-(2-phenoxyethyl)imidazo[4,5-c]quinoline Chemical compound CCCCC1=NC2=CN=C3C=CC=CC3=C2N1CCOC1=CC=CC=C1 MBPUDPUZEMFZSW-UHFFFAOYSA-N 0.000 description 2
- JSNMDHAMHWKQKZ-UHFFFAOYSA-N 2-butyl-1-(2-phenylmethoxyethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCOCC1=CC=CC=C1 JSNMDHAMHWKQKZ-UHFFFAOYSA-N 0.000 description 2
- GVUDYUDCKVZUQL-UHFFFAOYSA-N 2-butyl-1-[2-(3-phenylprop-2-ynoxy)ethyl]imidazo[4,5-c]quinoline Chemical compound CCCCC1=NC2=CN=C3C=CC=CC3=C2N1CCOCC#CC1=CC=CC=C1 GVUDYUDCKVZUQL-UHFFFAOYSA-N 0.000 description 2
- UBPICIQNBFNDIQ-UHFFFAOYSA-N 2-chloro-3-nitroquinolin-4-amine Chemical compound C1=CC=C2C(N)=C([N+]([O-])=O)C(Cl)=NC2=C1 UBPICIQNBFNDIQ-UHFFFAOYSA-N 0.000 description 2
- KERSAFJGNOGGQZ-UHFFFAOYSA-N 2-chloroquinoline-3,4-diamine Chemical compound C1=CC=C2N=C(Cl)C(N)=C(N)C2=C1 KERSAFJGNOGGQZ-UHFFFAOYSA-N 0.000 description 2
- NFLMRMLAPWTONF-UHFFFAOYSA-N 2-cyclopentyl-1-(2-phenoxyethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound C1CCCC1C1=NC=2C(N)=NC3=CC=CC=C3C=2N1CCOC1=CC=CC=C1 NFLMRMLAPWTONF-UHFFFAOYSA-N 0.000 description 2
- SKOBGLOJJGVOSV-UHFFFAOYSA-N 2-imidazo[4,5-c]quinolin-1-ylbutan-1-ol Chemical compound C1=CC=CC2=C3N(C(CO)CC)C=NC3=CN=C21 SKOBGLOJJGVOSV-UHFFFAOYSA-N 0.000 description 2
- FJRCKLSTTNPURD-UHFFFAOYSA-N 2-methyl-1-[2-(3-phenylprop-2-ynoxy)ethyl]-6,7,8,9-tetrahydroimidazo[4,5-c]quinolin-4-amine Chemical compound CC1=NC2=C(N)N=C3CCCCC3=C2N1CCOCC#CC1=CC=CC=C1 FJRCKLSTTNPURD-UHFFFAOYSA-N 0.000 description 2
- CQCBGAILQOZUQF-UHFFFAOYSA-N 2-methyl-1-[2-(3-phenylprop-2-ynoxy)ethyl]imidazo[4,5-c]quinoline Chemical compound CC1=NC2=CN=C3C=CC=CC3=C2N1CCOCC#CC1=CC=CC=C1 CQCBGAILQOZUQF-UHFFFAOYSA-N 0.000 description 2
- UJHWTLJEEZMABH-UHFFFAOYSA-N 2-methyl-1-[2-(3-phenylpropoxy)ethyl]imidazo[4,5-c]quinolin-4-amine Chemical compound CC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCOCCCC1=CC=CC=C1 UJHWTLJEEZMABH-UHFFFAOYSA-N 0.000 description 2
- VROYIZATBUFEKF-UHFFFAOYSA-N 2-methyl-1-[2-(3-phenylpropoxy)ethyl]imidazo[4,5-c]quinoline Chemical compound CC1=NC2=CN=C3C=CC=CC3=C2N1CCOCCCC1=CC=CC=C1 VROYIZATBUFEKF-UHFFFAOYSA-N 0.000 description 2
- QXMGBZQQDHSUBL-UHFFFAOYSA-N 2-octyl-1-(2-phenylmethoxyethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound CCCCCCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCOCC1=CC=CC=C1 QXMGBZQQDHSUBL-UHFFFAOYSA-N 0.000 description 2
- DDNZKDWUUPFDOD-UHFFFAOYSA-N 2-octyl-1-[2-(3-phenylpropoxy)ethyl]imidazo[4,5-c]quinolin-4-amine Chemical compound CCCCCCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCOCCCC1=CC=CC=C1 DDNZKDWUUPFDOD-UHFFFAOYSA-N 0.000 description 2
- BGGPFEDTPBJGDI-UHFFFAOYSA-N 2-octyl-1-[2-(3-phenylpropoxy)ethyl]imidazo[4,5-c]quinoline Chemical compound CCCCCCCCC1=NC2=CN=C3C=CC=CC3=C2N1CCOCCCC1=CC=CC=C1 BGGPFEDTPBJGDI-UHFFFAOYSA-N 0.000 description 2
- XMZQWZJMTBCUFT-UHFFFAOYSA-N 3-bromopropylbenzene Chemical compound BrCCCC1=CC=CC=C1 XMZQWZJMTBCUFT-UHFFFAOYSA-N 0.000 description 2
- LULAYUGMBFYYEX-UHFFFAOYSA-N 3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 2
- YLJKNCQDAUATPG-UHFFFAOYSA-N 3-nitro-n-(2-phenoxyethyl)quinolin-4-amine Chemical compound [O-][N+](=O)C1=CN=C2C=CC=CC2=C1NCCOC1=CC=CC=C1 YLJKNCQDAUATPG-UHFFFAOYSA-N 0.000 description 2
- SKPRPEJLFKCOAB-UHFFFAOYSA-N 3-nitroquinolin-4-amine Chemical compound C1=CC=C2C(N)=C([N+]([O-])=O)C=NC2=C1 SKPRPEJLFKCOAB-UHFFFAOYSA-N 0.000 description 2
- KOFZKASOTOVJDW-UHFFFAOYSA-N 4-(2-imidazo[4,5-c]quinolin-1-ylethoxymethyl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1COCCN1C2=C3C=CC=CC3=NC=C2N=C1 KOFZKASOTOVJDW-UHFFFAOYSA-N 0.000 description 2
- BODRCRUXAOATJG-UHFFFAOYSA-N 4-[2-(4-aminoimidazo[4,5-c]quinolin-1-yl)butoxymethyl]benzonitrile Chemical compound C1=NC2=C(N)N=C3C=CC=CC3=C2N1C(CC)COCC1=CC=C(C#N)C=C1 BODRCRUXAOATJG-UHFFFAOYSA-N 0.000 description 2
- BODRCRUXAOATJG-QGZVFWFLSA-N 4-[[(2r)-2-(4-aminoimidazo[4,5-c]quinolin-1-yl)butoxy]methyl]benzonitrile Chemical compound C([C@@H](CC)N1C2=C3C=CC=CC3=NC(N)=C2N=C1)OCC1=CC=C(C#N)C=C1 BODRCRUXAOATJG-QGZVFWFLSA-N 0.000 description 2
- BODRCRUXAOATJG-KRWDZBQOSA-N 4-[[(2s)-2-(4-aminoimidazo[4,5-c]quinolin-1-yl)butoxy]methyl]benzonitrile Chemical compound C([C@H](CC)N1C2=C3C=CC=CC3=NC(N)=C2N=C1)OCC1=CC=C(C#N)C=C1 BODRCRUXAOATJG-KRWDZBQOSA-N 0.000 description 2
- MRPICIZBNPEBTM-JXMROGBWSA-N 4-chloro-2-methyl-1-[2-[(e)-3-phenylprop-2-enoxy]ethyl]imidazo[4,5-c]quinoline Chemical compound CC1=NC2=C(Cl)N=C3C=CC=CC3=C2N1CCOC\C=C\C1=CC=CC=C1 MRPICIZBNPEBTM-JXMROGBWSA-N 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- KECQDPNQXDVFKO-UHFFFAOYSA-N 5-[3-[2-(4-aminoimidazo[4,5-c]quinolin-1-yl)ethoxy]propyl]-1,4-dimethylcyclohexa-2,4-diene-1-sulfonamide Chemical compound CC1(CC(=C(C=C1)C)CCCOCCN1C=NC=2C(=NC=3C=CC=CC=3C=21)N)S(=O)(=O)N KECQDPNQXDVFKO-UHFFFAOYSA-N 0.000 description 2
- VRUMYUAAFXCHHV-UHFFFAOYSA-N 5-chloro-4-nitrotetrazolo[1,5-a]quinoline Chemical compound [O-][N+](=O)C1=C(Cl)C2=CC=CC=C2N2C1=NN=N2 VRUMYUAAFXCHHV-UHFFFAOYSA-N 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- PKVMMGWDABXLLX-GFCCVEGCSA-N [(2r)-2-imidazo[4,5-c]quinolin-1-ylbutyl] acetate Chemical compound C1=CC=CC2=C3N([C@@H](COC(C)=O)CC)C=NC3=CN=C21 PKVMMGWDABXLLX-GFCCVEGCSA-N 0.000 description 2
- 150000001266 acyl halides Chemical class 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 125000005236 alkanoylamino group Chemical group 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 125000005333 aroyloxy group Chemical group 0.000 description 2
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- 125000005129 aryl carbonyl group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000012320 chlorinating reagent Substances 0.000 description 2
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 150000004985 diamines Chemical class 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 125000004995 haloalkylthio group Chemical group 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 125000005114 heteroarylalkoxy group Chemical group 0.000 description 2
- 125000005367 heteroarylalkylthio group Chemical group 0.000 description 2
- 125000005553 heteroaryloxy group Chemical group 0.000 description 2
- 125000005368 heteroarylthio group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 238000009904 heterogeneous catalytic hydrogenation reaction Methods 0.000 description 2
- NSHFLKZNBPJNPA-UHFFFAOYSA-N imidazo[4,5-c]quinolin-2-one Chemical class C1=CC=C2C3=NC(=O)N=C3C=NC2=C1 NSHFLKZNBPJNPA-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 229940087646 methanolamine Drugs 0.000 description 2
- OAMGJXSIONONIS-UHFFFAOYSA-N n-[2-butyl-1-(2-phenylmethoxyethyl)imidazo[4,5-c]quinolin-4-yl]-2,2,2-trichloroacetamide Chemical compound CCCCC1=NC2=C(NC(=O)C(Cl)(Cl)Cl)N=C3C=CC=CC3=C2N1CCOCC1=CC=CC=C1 OAMGJXSIONONIS-UHFFFAOYSA-N 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-M phenolate Chemical compound [O-]C1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-M 0.000 description 2
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- GNZIHPAAJVXCAS-UHFFFAOYSA-N quinolin-4-amine;hydrochloride Chemical compound Cl.C1=CC=C2C(N)=CC=NC2=C1 GNZIHPAAJVXCAS-UHFFFAOYSA-N 0.000 description 2
- UTOMICFLROGMAE-UHFFFAOYSA-N quinoline-3,4-diamine Chemical compound C1=CC=CC2=C(N)C(N)=CN=C21 UTOMICFLROGMAE-UHFFFAOYSA-N 0.000 description 2
- 150000003248 quinolines Chemical class 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 150000003738 xylenes Chemical class 0.000 description 2
- JCBPETKZIGVZRE-SCSAIBSYSA-N (2r)-2-aminobutan-1-ol Chemical compound CC[C@@H](N)CO JCBPETKZIGVZRE-SCSAIBSYSA-N 0.000 description 1
- IZQFGNYJJLLKJX-MRVPVSSYSA-N (2r)-3-[(3-amino-2-chloroquinolin-4-yl)amino]-2-methylpropan-1-ol Chemical compound C1=CC=C2C(NC[C@H](CO)C)=C(N)C(Cl)=NC2=C1 IZQFGNYJJLLKJX-MRVPVSSYSA-N 0.000 description 1
- FVXBTPGZQMNAEZ-SCSAIBSYSA-N (2r)-3-amino-2-methylpropan-1-ol Chemical compound NC[C@@H](C)CO FVXBTPGZQMNAEZ-SCSAIBSYSA-N 0.000 description 1
- SKOBGLOJJGVOSV-JTQLQIEISA-N (2s)-2-imidazo[4,5-c]quinolin-1-ylbutan-1-ol Chemical compound C1=CC=CC2=C3N([C@H](CO)CC)C=NC3=CN=C21 SKOBGLOJJGVOSV-JTQLQIEISA-N 0.000 description 1
- SYSZENVIJHPFNL-UHFFFAOYSA-N (alpha-D-mannosyl)7-beta-D-mannosyl-diacetylchitobiosyl-L-asparagine, isoform B (protein) Chemical compound COC1=CC=C(I)C=C1 SYSZENVIJHPFNL-UHFFFAOYSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- NDQXKKFRNOPRDW-UHFFFAOYSA-N 1,1,1-triethoxyethane Chemical compound CCOC(C)(OCC)OCC NDQXKKFRNOPRDW-UHFFFAOYSA-N 0.000 description 1
- PBFXPRHQMCTJGF-UHFFFAOYSA-N 1-(2-phenoxyethyl)-2-phenylimidazo[4,5-c]quinolin-4-amine Chemical compound C=1C=CC=CC=1C1=NC=2C(N)=NC3=CC=CC=C3C=2N1CCOC1=CC=CC=C1 PBFXPRHQMCTJGF-UHFFFAOYSA-N 0.000 description 1
- PZXZPCAYBGIEJI-UHFFFAOYSA-N 1-(2-phenoxyethyl)-2-propan-2-ylimidazo[4,5-c]quinolin-4-amine Chemical compound CC(C)C1=NC2=C(N)N=C3C=CC=CC3=C2N1CCOC1=CC=CC=C1 PZXZPCAYBGIEJI-UHFFFAOYSA-N 0.000 description 1
- RRNSSBQJUIHXSN-UHFFFAOYSA-N 1-(2-phenoxyethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound C1=NC=2C(N)=NC3=CC=CC=C3C=2N1CCOC1=CC=CC=C1 RRNSSBQJUIHXSN-UHFFFAOYSA-N 0.000 description 1
- YJKZDGOMTKOYQK-UHFFFAOYSA-N 1-(2-piperidin-4-ylethyl)imidazo[4,5-c]quinoline Chemical compound C1=NC2=CN=C3C=CC=CC3=C2N1CCC1CCNCC1 YJKZDGOMTKOYQK-UHFFFAOYSA-N 0.000 description 1
- IGQBRFYUGGWUBH-UHFFFAOYSA-N 1-(4-aminoimidazo[4,5-c]quinolin-1-yl)propan-2-ol Chemical compound C1=CC=CC2=C3N(CC(O)C)C=NC3=C(N)N=C21 IGQBRFYUGGWUBH-UHFFFAOYSA-N 0.000 description 1
- FMURNAZHVQDQQN-UHFFFAOYSA-N 1-(4-iodophenyl)pyrrole Chemical compound C1=CC(I)=CC=C1N1C=CC=C1 FMURNAZHVQDQQN-UHFFFAOYSA-N 0.000 description 1
- HDDNSPWJCZZICL-UHFFFAOYSA-N 1-(6-methoxyquinolin-8-yl)-2-methylimidazo[4,5-c]quinoline Chemical compound N1=CC=CC2=CC(OC)=CC(N3C4=C5C=CC=CC5=NC=C4N=C3C)=C21 HDDNSPWJCZZICL-UHFFFAOYSA-N 0.000 description 1
- LZIYAIRGDHSVED-UHFFFAOYSA-N 1-(bromomethyl)-3-chlorobenzene Chemical compound ClC1=CC=CC(CBr)=C1 LZIYAIRGDHSVED-UHFFFAOYSA-N 0.000 description 1
- CZJBOKJIPCNOSB-UHFFFAOYSA-N 1-(phenylmethoxymethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound C1=NC=2C(N)=NC3=CC=CC=C3C=2N1COCC1=CC=CC=C1 CZJBOKJIPCNOSB-UHFFFAOYSA-N 0.000 description 1
- KZJZYYSGTLBGBS-GFCCVEGCSA-N 1-[(2r)-1-prop-2-ynoxybutan-2-yl]imidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C3N([C@@H](COCC#C)CC)C=NC3=C(N)N=C21 KZJZYYSGTLBGBS-GFCCVEGCSA-N 0.000 description 1
- NJHQEMGWDHCDHQ-CYBMUJFWSA-N 1-[(2r)-1-prop-2-ynoxybutan-2-yl]imidazo[4,5-c]quinoline Chemical compound C1=CC=CC2=C3N([C@@H](COCC#C)CC)C=NC3=CN=C21 NJHQEMGWDHCDHQ-CYBMUJFWSA-N 0.000 description 1
- AGPSJNYGUDVJDZ-UHFFFAOYSA-N 1-[1-[(3-chlorophenyl)methoxy]butan-2-yl]imidazo[4,5-c]quinolin-4-amine Chemical compound C1=NC2=C(N)N=C3C=CC=CC3=C2N1C(CC)COCC1=CC=CC(Cl)=C1 AGPSJNYGUDVJDZ-UHFFFAOYSA-N 0.000 description 1
- HORGXZVRQJFBQU-UHFFFAOYSA-N 1-[1-[(3-chlorophenyl)methoxy]butan-2-yl]imidazo[4,5-c]quinoline Chemical compound C1=NC2=CN=C3C=CC=CC3=C2N1C(CC)COCC1=CC=CC(Cl)=C1 HORGXZVRQJFBQU-UHFFFAOYSA-N 0.000 description 1
- WVWKUNHGONTMSJ-UHFFFAOYSA-N 1-[2-(3-phenylpropoxy)ethyl]imidazo[4,5-c]quinolin-4-amine Chemical compound C1=NC=2C(N)=NC3=CC=CC=C3C=2N1CCOCCCC1=CC=CC=C1 WVWKUNHGONTMSJ-UHFFFAOYSA-N 0.000 description 1
- BXYYXWFYQWVEQO-RMKNXTFCSA-N 1-[2-[(e)-3-phenylprop-2-enoxy]ethyl]imidazo[4,5-c]quinoline Chemical compound C1=NC2=CN=C3C=CC=CC3=C2N1CCOC\C=C\C1=CC=CC=C1 BXYYXWFYQWVEQO-RMKNXTFCSA-N 0.000 description 1
- VTWLCSHTCUBCCC-UHFFFAOYSA-N 1-[2-[3-(2,6-dimethylphenyl)prop-2-ynoxy]ethyl]imidazo[4,5-c]quinolin-4-amine Chemical compound CC1=CC=CC(C)=C1C#CCOCCN1C2=C3C=CC=CC3=NC(N)=C2N=C1 VTWLCSHTCUBCCC-UHFFFAOYSA-N 0.000 description 1
- YKTLQEOAAZRCKE-UHFFFAOYSA-N 1-[2-[3-(3,4-dimethylphenyl)prop-2-ynoxy]ethyl]imidazo[4,5-c]quinolin-4-amine Chemical compound C1=C(C)C(C)=CC=C1C#CCOCCN1C2=C3C=CC=CC3=NC(N)=C2N=C1 YKTLQEOAAZRCKE-UHFFFAOYSA-N 0.000 description 1
- MUANTTGMTMMTSY-UHFFFAOYSA-N 1-[2-[3-(4-methoxyphenyl)propoxy]ethyl]imidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC(OC)=CC=C1CCCOCCN1C2=C3C=CC=CC3=NC(N)=C2N=C1 MUANTTGMTMMTSY-UHFFFAOYSA-N 0.000 description 1
- UDZRXWXXROIEMA-UHFFFAOYSA-N 1-[2-[3-(4-phenoxyphenyl)prop-2-ynoxy]ethyl]imidazo[4,5-c]quinolin-4-amine Chemical compound C1=NC=2C(N)=NC3=CC=CC=C3C=2N1CCOCC#CC(C=C1)=CC=C1OC1=CC=CC=C1 UDZRXWXXROIEMA-UHFFFAOYSA-N 0.000 description 1
- MALWGDJCHVCLTN-UHFFFAOYSA-N 1-[2-[3-(4-pyrrol-1-ylphenyl)propoxy]ethyl]imidazo[4,5-c]quinolin-4-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=NC=2C(N)=NC3=CC=CC=C3C=2N1CCOCCCC(C=C1)=CC=C1N1C=CC=C1 MALWGDJCHVCLTN-UHFFFAOYSA-N 0.000 description 1
- OUPPOYKJGLJBGA-UHFFFAOYSA-N 1-[2-[3-[2-(trifluoromethyl)phenyl]prop-2-ynoxy]ethyl]imidazo[4,5-c]quinolin-4-amine Chemical compound C1=NC=2C(N)=NC3=CC=CC=C3C=2N1CCOCC#CC1=CC=CC=C1C(F)(F)F OUPPOYKJGLJBGA-UHFFFAOYSA-N 0.000 description 1
- MWKQWCGEDBTQIW-UHFFFAOYSA-N 1-[2-[3-[3-(dimethylamino)phenyl]prop-2-ynoxy]ethyl]imidazo[4,5-c]quinolin-4-amine Chemical compound CN(C)C1=CC=CC(C#CCOCCN2C3=C4C=CC=CC4=NC(N)=C3N=C2)=C1 MWKQWCGEDBTQIW-UHFFFAOYSA-N 0.000 description 1
- PKWYDYNYHFGUID-UHFFFAOYSA-N 1-[2-[3-[3-(dimethylamino)phenyl]propoxy]ethyl]imidazo[4,5-c]quinolin-4-amine Chemical compound CN(C)C1=CC=CC(CCCOCCN2C3=C4C=CC=CC4=NC(N)=C3N=C2)=C1 PKWYDYNYHFGUID-UHFFFAOYSA-N 0.000 description 1
- JEJUNJMVZLMGRX-UHFFFAOYSA-N 1-[2-[3-[4-(dimethylamino)phenyl]propoxy]ethyl]imidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC(N(C)C)=CC=C1CCCOCCN1C2=C3C=CC=CC3=NC(N)=C2N=C1 JEJUNJMVZLMGRX-UHFFFAOYSA-N 0.000 description 1
- IGZGUYVVBABKOY-UHFFFAOYSA-N 1-iodo-2-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1I IGZGUYVVBABKOY-UHFFFAOYSA-N 0.000 description 1
- BDKOUDYNKRCDEC-UHFFFAOYSA-N 1-iodo-4-phenoxybenzene Chemical compound C1=CC(I)=CC=C1OC1=CC=CC=C1 BDKOUDYNKRCDEC-UHFFFAOYSA-N 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical group C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- UHUHBFMZVCOEOV-UHFFFAOYSA-N 1h-imidazo[4,5-c]pyridin-4-amine Chemical class NC1=NC=CC2=C1N=CN2 UHUHBFMZVCOEOV-UHFFFAOYSA-N 0.000 description 1
- HFKBIASMQSNUNT-UHFFFAOYSA-N 2,2,2-trichloro-n-[1-(2-prop-2-ynoxyethyl)imidazo[4,5-c]quinolin-4-yl]acetamide Chemical compound ClC(Cl)(Cl)C(=O)NC1=NC2=CC=CC=C2C2=C1N=CN2CCOCC#C HFKBIASMQSNUNT-UHFFFAOYSA-N 0.000 description 1
- HLFGXPKPTDQYBN-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-imidazo[4,5-c]quinolin-4-amine Chemical class NC1N=C2C=CC=CC2=C2C1NCN2 HLFGXPKPTDQYBN-UHFFFAOYSA-N 0.000 description 1
- SSDYFZUPEUFHOR-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-imidazo[4,5-c]quinoline Chemical class C1N=C2C=CC=CC2=C2C1NCN2 SSDYFZUPEUFHOR-UHFFFAOYSA-N 0.000 description 1
- VRJBJPNTHSJHNO-UHFFFAOYSA-N 2-(2-butylimidazo[4,5-c]quinolin-1-yl)ethanol Chemical compound C1=CC=CC2=C(N(C(CCCC)=N3)CCO)C3=CN=C21 VRJBJPNTHSJHNO-UHFFFAOYSA-N 0.000 description 1
- OZJZCCMIOZPPIT-UHFFFAOYSA-N 2-(2-methoxyethoxy)acetyl chloride Chemical compound COCCOCC(Cl)=O OZJZCCMIOZPPIT-UHFFFAOYSA-N 0.000 description 1
- HHJCDRCNIVACLC-UHFFFAOYSA-N 2-(2-methoxyethoxymethyl)-1-(2-phenoxyethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound COCCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCOC1=CC=CC=C1 HHJCDRCNIVACLC-UHFFFAOYSA-N 0.000 description 1
- YCKTUJUCPSZDRL-UHFFFAOYSA-N 2-(2-methoxyethyl)-1-(2-phenoxyethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound COCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCOC1=CC=CC=C1 YCKTUJUCPSZDRL-UHFFFAOYSA-N 0.000 description 1
- FHOIYTWXEZFHSU-UHFFFAOYSA-N 2-(2-methoxyethyl)-1-(2-phenoxyethyl)imidazo[4,5-c]quinoline Chemical compound COCCC1=NC2=CN=C3C=CC=CC3=C2N1CCOC1=CC=CC=C1 FHOIYTWXEZFHSU-UHFFFAOYSA-N 0.000 description 1
- IADZVQPUOIFOAS-UHFFFAOYSA-N 2-(2-methoxyethyl)-1-(2-prop-2-ynoxyethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C(N(C(CCOC)=N3)CCOCC#C)C3=C(N)N=C21 IADZVQPUOIFOAS-UHFFFAOYSA-N 0.000 description 1
- RRCGFYNJSZDIIC-UHFFFAOYSA-N 2-(2-methylimidazo[4,5-c]quinolin-1-yl)ethanol Chemical compound C1=CC=CC2=C(N(C(C)=N3)CCO)C3=CN=C21 RRCGFYNJSZDIIC-UHFFFAOYSA-N 0.000 description 1
- RXYDHTQGIGZYRS-UHFFFAOYSA-N 2-(2-octylimidazo[4,5-c]quinolin-1-yl)ethanol Chemical compound C1=CC=CC2=C(N(C(CCCCCCCC)=N3)CCO)C3=CN=C21 RXYDHTQGIGZYRS-UHFFFAOYSA-N 0.000 description 1
- GWKOUFONUAPOOX-UHFFFAOYSA-N 2-(4-amino-2-butyl-6,7,8,9-tetrahydroimidazo[4,5-c]quinolin-1-yl)ethanol Chemical compound C1CCCC2=C(N(C(CCCC)=N3)CCO)C3=C(N)N=C21 GWKOUFONUAPOOX-UHFFFAOYSA-N 0.000 description 1
- FTFLLMCMGJUFHH-UHFFFAOYSA-N 2-(4-amino-2-methyl-6,7,8,9-tetrahydroimidazo[4,5-c]quinolin-1-yl)ethanol Chemical compound C1CCCC2=C(N(C(C)=N3)CCO)C3=C(N)N=C21 FTFLLMCMGJUFHH-UHFFFAOYSA-N 0.000 description 1
- OWKZMVASJFEUKK-UHFFFAOYSA-N 2-(4-aminoimidazo[4,5-c]quinolin-1-yl)ethanol Chemical compound NC1=NC2=CC=CC=C2C2=C1N=CN2CCO OWKZMVASJFEUKK-UHFFFAOYSA-N 0.000 description 1
- DZHBNLIWBDDPFU-UHFFFAOYSA-N 2-(4-chloro-2-methylimidazo[4,5-c]quinolin-1-yl)ethyl acetate Chemical compound C1=CC=CC2=C3N(CCOC(=O)C)C(C)=NC3=C(Cl)N=C21 DZHBNLIWBDDPFU-UHFFFAOYSA-N 0.000 description 1
- CXJOONIFSVSFAD-UHFFFAOYSA-N 2-(4-methoxyphenyl)acetyl chloride Chemical compound COC1=CC=C(CC(Cl)=O)C=C1 CXJOONIFSVSFAD-UHFFFAOYSA-N 0.000 description 1
- BAXBTCGNKQUUBA-UHFFFAOYSA-N 2-(ethoxymethyl)-1-(2-phenylmethoxyethyl)imidazo[4,5-c]quinoline Chemical compound CCOCC1=NC2=CN=C3C=CC=CC3=C2N1CCOCC1=CC=CC=C1 BAXBTCGNKQUUBA-UHFFFAOYSA-N 0.000 description 1
- GTRXPFNPHWINQX-UHFFFAOYSA-N 2-(ethoxymethyl)-1-(2-prop-2-ynoxyethyl)imidazo[4,5-c]quinoline Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CCOCC#C)C3=CN=C21 GTRXPFNPHWINQX-UHFFFAOYSA-N 0.000 description 1
- DITHACKITKTCMN-UHFFFAOYSA-N 2-(ethoxymethyl)-1-[2-(3-phenylmethoxypropoxy)ethyl]imidazo[4,5-c]quinolin-4-amine Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCOCCCOCC1=CC=CC=C1 DITHACKITKTCMN-UHFFFAOYSA-N 0.000 description 1
- YDQRACKJUMQWBF-UHFFFAOYSA-N 2-(ethoxymethyl)-1-[2-(3-phenylpropoxy)ethyl]imidazo[4,5-c]quinolin-4-amine;hydrochloride Chemical compound Cl.CCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCOCCCC1=CC=CC=C1 YDQRACKJUMQWBF-UHFFFAOYSA-N 0.000 description 1
- LQWVLNYMFITWCA-UHFFFAOYSA-N 2-(ethoxymethyl)-1-[2-(3-phenylpropoxy)ethyl]imidazo[4,5-c]quinoline Chemical compound CCOCC1=NC2=CN=C3C=CC=CC3=C2N1CCOCCCC1=CC=CC=C1 LQWVLNYMFITWCA-UHFFFAOYSA-N 0.000 description 1
- PNZKQSQQKSYYAL-UHFFFAOYSA-N 2-(ethoxymethyl)-1-[2-[6-(4-phenylbutoxy)hexoxy]ethyl]imidazo[4,5-c]quinoline Chemical compound CCOCC1=NC2=CN=C3C=CC=CC3=C2N1CCOCCCCCCOCCCCC1=CC=CC=C1 PNZKQSQQKSYYAL-UHFFFAOYSA-N 0.000 description 1
- CEPZKBSZAZTUPK-UHFFFAOYSA-N 2-(oxolan-3-yl)-1-(2-phenoxyethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound C1COCC1C1=NC=2C(N)=NC3=CC=CC=C3C=2N1CCOC1=CC=CC=C1 CEPZKBSZAZTUPK-UHFFFAOYSA-N 0.000 description 1
- WJLUZDZCYNAPSZ-UHFFFAOYSA-N 2-[3-[2-(4-aminoimidazo[4,5-c]quinolin-1-yl)ethoxy]propyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=NC=2C(N)=NC3=CC=CC=C3C=2N1CCOCCCC1=CC=CC=C1C(O)=O WJLUZDZCYNAPSZ-UHFFFAOYSA-N 0.000 description 1
- CZYQLBVCCUQJJE-UHFFFAOYSA-N 2-butyl-1-(2-phenylmethoxyethyl)imidazo[4,5-c]quinoline Chemical compound CCCCC1=NC2=CN=C3C=CC=CC3=C2N1CCOCC1=CC=CC=C1 CZYQLBVCCUQJJE-UHFFFAOYSA-N 0.000 description 1
- HVUNRNBKDJFYDC-UHFFFAOYSA-N 2-butyl-1-(2-prop-2-ynoxyethyl)imidazo[4,5-c]quinoline Chemical compound C1=CC=CC2=C(N(C(CCCC)=N3)CCOCC#C)C3=CN=C21 HVUNRNBKDJFYDC-UHFFFAOYSA-N 0.000 description 1
- VAOFNSPAPRTXMV-UHFFFAOYSA-N 2-butyl-1-[2-(3-phenylprop-2-ynoxy)ethyl]imidazo[4,5-c]quinolin-4-amine Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCOCC#CC1=CC=CC=C1 VAOFNSPAPRTXMV-UHFFFAOYSA-N 0.000 description 1
- RBDYDUBIVMVSQP-UHFFFAOYSA-N 2-butyl-1-[2-(3-phenylpropoxy)ethyl]imidazo[4,5-c]quinolin-4-amine Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCOCCCC1=CC=CC=C1 RBDYDUBIVMVSQP-UHFFFAOYSA-N 0.000 description 1
- RWEVHIBGZYPOKF-UHFFFAOYSA-N 2-butyl-1-[2-(3-phenylpropoxy)ethyl]imidazo[4,5-c]quinoline Chemical compound CCCCC1=NC2=CN=C3C=CC=CC3=C2N1CCOCCCC1=CC=CC=C1 RWEVHIBGZYPOKF-UHFFFAOYSA-N 0.000 description 1
- IALGRRFZGRXFKT-UHFFFAOYSA-N 2-cyclopropylacetyl chloride Chemical compound ClC(=O)CC1CC1 IALGRRFZGRXFKT-UHFFFAOYSA-N 0.000 description 1
- QTUGGVBKWIYQSS-UHFFFAOYSA-N 2-iodo-1,3-dimethylbenzene Chemical compound CC1=CC=CC(C)=C1I QTUGGVBKWIYQSS-UHFFFAOYSA-N 0.000 description 1
- UBPDKIDWEADHPP-UHFFFAOYSA-N 2-iodoaniline Chemical compound NC1=CC=CC=C1I UBPDKIDWEADHPP-UHFFFAOYSA-N 0.000 description 1
- JDDAFHUEOVUDFJ-UHFFFAOYSA-N 2-iodobenzonitrile Chemical compound IC1=CC=CC=C1C#N JDDAFHUEOVUDFJ-UHFFFAOYSA-N 0.000 description 1
- LSHPFONCFARITF-UHFFFAOYSA-N 2-methyl-1-(2-phenylmethoxyethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound CC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCOCC1=CC=CC=C1 LSHPFONCFARITF-UHFFFAOYSA-N 0.000 description 1
- UDAWYVSATRYRQF-UHFFFAOYSA-N 2-methyl-1-(2-phenylmethoxyethyl)imidazo[4,5-c]quinoline Chemical compound CC1=NC2=CN=C3C=CC=CC3=C2N1CCOCC1=CC=CC=C1 UDAWYVSATRYRQF-UHFFFAOYSA-N 0.000 description 1
- KSVMKGJOVUQTFG-UHFFFAOYSA-N 2-methyl-1-(2-prop-2-ynoxyethyl)-6,7,8,9-tetrahydroimidazo[4,5-c]quinolin-4-amine Chemical compound C1CCCC2=C(N(C(C)=N3)CCOCC#C)C3=C(N)N=C21 KSVMKGJOVUQTFG-UHFFFAOYSA-N 0.000 description 1
- MEHAGDPISBJOGQ-UHFFFAOYSA-N 2-methyl-1-(2-prop-2-ynoxyethyl)imidazo[4,5-c]quinoline Chemical compound C1=CC=CC2=C(N(C(C)=N3)CCOCC#C)C3=CN=C21 MEHAGDPISBJOGQ-UHFFFAOYSA-N 0.000 description 1
- FORUIBHRCDOMLL-JXMROGBWSA-N 2-methyl-1-[2-[(e)-3-phenylprop-2-enoxy]ethyl]imidazo[4,5-c]quinolin-4-amine Chemical compound CC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCOC\C=C\C1=CC=CC=C1 FORUIBHRCDOMLL-JXMROGBWSA-N 0.000 description 1
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
- KVVHCCXMHZXZNM-UHFFFAOYSA-N 2-octyl-1-(2-phenylmethoxyethyl)imidazo[4,5-c]quinoline Chemical compound CCCCCCCCC1=NC2=CN=C3C=CC=CC3=C2N1CCOCC1=CC=CC=C1 KVVHCCXMHZXZNM-UHFFFAOYSA-N 0.000 description 1
- HWLMICSGSZEOFJ-UHFFFAOYSA-N 2-octyl-1-(2-prop-2-ynoxyethyl)imidazo[4,5-c]quinoline Chemical compound C1=CC=CC2=C(N(C(CCCCCCCC)=N3)CCOCC#C)C3=CN=C21 HWLMICSGSZEOFJ-UHFFFAOYSA-N 0.000 description 1
- XNUQRFUJTBLYIV-UHFFFAOYSA-N 2-octyl-1-[2-(3-phenylprop-2-ynoxy)ethyl]imidazo[4,5-c]quinolin-4-amine Chemical compound CCCCCCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCOCC#CC1=CC=CC=C1 XNUQRFUJTBLYIV-UHFFFAOYSA-N 0.000 description 1
- PKUPAJQAJXVUEK-UHFFFAOYSA-N 2-phenoxyacetyl chloride Chemical compound ClC(=O)COC1=CC=CC=C1 PKUPAJQAJXVUEK-UHFFFAOYSA-N 0.000 description 1
- IMLAIXAZMVDRGA-UHFFFAOYSA-N 2-phenoxyethanamine Chemical compound NCCOC1=CC=CC=C1 IMLAIXAZMVDRGA-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- YYFLDZZDOUDZQM-UHFFFAOYSA-N 3-[1-[[4-(3-phenylquinolin-2-yl)phenyl]methyl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC=CC=C2N1C(CC1)CCN1CC(C=C1)=CC=C1C1=NC2=CC=CC=C2C=C1C1=CC=CC=C1 YYFLDZZDOUDZQM-UHFFFAOYSA-N 0.000 description 1
- FKKOENISNWVPLQ-UHFFFAOYSA-N 3-[3-[2-(4-aminoimidazo[4,5-c]quinolin-1-yl)ethoxy]propyl]benzoic acid Chemical compound C1=NC=2C(N)=NC3=CC=CC=C3C=2N1CCOCCCC1=CC=CC(C(O)=O)=C1 FKKOENISNWVPLQ-UHFFFAOYSA-N 0.000 description 1
- RUROFEVDCUGKHD-UHFFFAOYSA-N 3-bromoprop-1-enylbenzene Chemical compound BrCC=CC1=CC=CC=C1 RUROFEVDCUGKHD-UHFFFAOYSA-N 0.000 description 1
- PSUXTZLDBVEZTD-UHFFFAOYSA-N 3-bromopropoxymethylbenzene Chemical compound BrCCCOCC1=CC=CC=C1 PSUXTZLDBVEZTD-UHFFFAOYSA-N 0.000 description 1
- SZQVEGOXJYTLLB-UHFFFAOYSA-N 3-cyclopentylpropanoyl chloride Chemical compound ClC(=O)CCC1CCCC1 SZQVEGOXJYTLLB-UHFFFAOYSA-N 0.000 description 1
- TVFNKBQQVHGWAF-UHFFFAOYSA-N 3-iodo-n,n-dimethylaniline Chemical compound CN(C)C1=CC=CC(I)=C1 TVFNKBQQVHGWAF-UHFFFAOYSA-N 0.000 description 1
- KVBWBCRPWVKFQT-UHFFFAOYSA-M 3-iodobenzoate Chemical compound [O-]C(=O)C1=CC=CC(I)=C1 KVBWBCRPWVKFQT-UHFFFAOYSA-M 0.000 description 1
- OTDRANPJFNPDHJ-UHFFFAOYSA-N 3-methoxy-n-[4-(2-phenoxyethylamino)quinolin-3-yl]propanamide Chemical compound COCCC(=O)NC1=CN=C2C=CC=CC2=C1NCCOC1=CC=CC=C1 OTDRANPJFNPDHJ-UHFFFAOYSA-N 0.000 description 1
- JSMDUOFOPDSKIQ-UHFFFAOYSA-N 3-methoxypropanoyl chloride Chemical compound COCCC(Cl)=O JSMDUOFOPDSKIQ-UHFFFAOYSA-N 0.000 description 1
- ISULZYQDGYXDFW-UHFFFAOYSA-N 3-methylbutanoyl chloride Chemical compound CC(C)CC(Cl)=O ISULZYQDGYXDFW-UHFFFAOYSA-N 0.000 description 1
- 125000006192 3-phenylprop-2-enyl group Chemical group [H]\C(=C(\[H])C([H])([H])*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- FCNHARPAFUWGKR-UHFFFAOYSA-N 3H-imidazo[4,5-c]quinolin-4-ylcarbamic acid Chemical compound OC(=O)NC1=NC2=CC=CC=C2C2=C1NC=N2 FCNHARPAFUWGKR-UHFFFAOYSA-N 0.000 description 1
- KGEGVJJFFQXJTG-UHFFFAOYSA-N 3h-imidazo[4,5-c][1,8]naphthyridin-4-amine Chemical class NC1=NC2=NC=CC=C2C2=C1N=CN2 KGEGVJJFFQXJTG-UHFFFAOYSA-N 0.000 description 1
- SVNAOMOUTKTRTE-UHFFFAOYSA-N 4-(2-imidazo[4,5-c]quinolin-1-ylbutoxymethyl)benzonitrile Chemical compound C1=NC2=CN=C3C=CC=CC3=C2N1C(CC)COCC1=CC=C(C#N)C=C1 SVNAOMOUTKTRTE-UHFFFAOYSA-N 0.000 description 1
- HYRIAERKUPZOCS-UHFFFAOYSA-N 4-(6-bromohexoxy)butylbenzene Chemical compound BrCCCCCCOCCCCC1=CC=CC=C1 HYRIAERKUPZOCS-UHFFFAOYSA-N 0.000 description 1
- UMLFTCYAQPPZER-UHFFFAOYSA-N 4-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=C(C#N)C=C1 UMLFTCYAQPPZER-UHFFFAOYSA-N 0.000 description 1
- HLISLTWXFBXMLE-UHFFFAOYSA-N 4-[2-(4-aminoimidazo[4,5-c]quinolin-1-yl)ethoxymethyl]benzonitrile Chemical compound C1=NC=2C(N)=NC3=CC=CC=C3C=2N1CCOCC1=CC=C(C#N)C=C1 HLISLTWXFBXMLE-UHFFFAOYSA-N 0.000 description 1
- OZKAAWPGAUXRPI-UHFFFAOYSA-N 4-[3-[2-(4-aminoimidazo[4,5-c]quinolin-1-yl)ethoxy]propyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=NC=2C(N)=NC3=CC=CC=C3C=2N1CCOCCCC1=CC=C(C(O)=O)C=C1 OZKAAWPGAUXRPI-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- QYOPPZJZMFMBDN-UHFFFAOYSA-N 4-iodo-n,n-dimethylaniline Chemical compound CN(C)C1=CC=C(I)C=C1 QYOPPZJZMFMBDN-UHFFFAOYSA-N 0.000 description 1
- HZJIVLDPBZTDHB-UHFFFAOYSA-N 4-nitrotetrazolo[1,5-a]quinolin-5-amine Chemical compound C1=CC=C2C(N)=C([N+]([O-])=O)C3=NN=NN3C2=C1 HZJIVLDPBZTDHB-UHFFFAOYSA-N 0.000 description 1
- JTKVJIJQXNQAAI-UHFFFAOYSA-N 4-phenoxy-1-(4-phenoxyimidazo[4,5-c]quinolin-1-yl)oxyimidazo[4,5-c]quinoline Chemical compound N=1C2=CC=CC=C2C=2N(ON3C4=C5C=CC=CC5=NC(OC=5C=CC=CC=5)=C4N=C3)C=NC=2C=1OC1=CC=CC=C1 JTKVJIJQXNQAAI-UHFFFAOYSA-N 0.000 description 1
- OYTRPNUFEBDWKQ-UHFFFAOYSA-N 4-phenoxy-3h-imidazo[4,5-c]quinoline Chemical compound N=1C2=CC=CC=C2C=2NC=NC=2C=1OC1=CC=CC=C1 OYTRPNUFEBDWKQ-UHFFFAOYSA-N 0.000 description 1
- YSNHPEOMRYCSKI-UHFFFAOYSA-N 4-phenoxy-6,7,8,9-tetrahydro-3h-imidazo[4,5-c]quinoline Chemical compound C1CCCC(C=2NC=NC=22)=C1N=C2OC1=CC=CC=C1 YSNHPEOMRYCSKI-UHFFFAOYSA-N 0.000 description 1
- 125000003836 4-phenylbutoxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000013165 Bowen disease Diseases 0.000 description 1
- 208000019337 Bowen disease of the skin Diseases 0.000 description 1
- VELKAUGRMHWKQT-UHFFFAOYSA-N C1=CC=C2C(O)=C([N+]([O-])=O)C3=NN=NN3C2=C1 Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C3=NN=NN3C2=C1 VELKAUGRMHWKQT-UHFFFAOYSA-N 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 208000006081 Cryptococcal meningitis Diseases 0.000 description 1
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 241000250507 Gigaspora candida Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 206010027209 Meningitis cryptococcal Diseases 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- XTZNCVSCVHTPAI-UHFFFAOYSA-N Salmeterol xinafoate Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21.C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 XTZNCVSCVHTPAI-UHFFFAOYSA-N 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- IWTYTFSSTWXZFU-QPJJXVBHSA-N [(e)-3-chloroprop-1-enyl]benzene Chemical compound ClC\C=C\C1=CC=CC=C1 IWTYTFSSTWXZFU-QPJJXVBHSA-N 0.000 description 1
- GLYOPNLBKCBTMI-UHFFFAOYSA-N [2-chloro-2-(1-chloro-2-phenylethoxy)ethyl]benzene Chemical compound C=1C=CC=CC=1CC(Cl)OC(Cl)CC1=CC=CC=C1 GLYOPNLBKCBTMI-UHFFFAOYSA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000005090 alkenylcarbonyl group Chemical group 0.000 description 1
- 125000005091 alkenylcarbonylamino group Chemical group 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000004949 alkyl amino carbonyl amino group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 description 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000005239 aroylamino group Chemical group 0.000 description 1
- 125000005126 aryl alkyl carbonyl amino group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 1
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- LURYMYITPCOQAU-UHFFFAOYSA-N benzoyl isocyanate Chemical compound O=C=NC(=O)C1=CC=CC=C1 LURYMYITPCOQAU-UHFFFAOYSA-N 0.000 description 1
- UKBDDEPFPQQLBR-UHFFFAOYSA-N benzyl 2-iodobenzoate Chemical compound IC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 UKBDDEPFPQQLBR-UHFFFAOYSA-N 0.000 description 1
- MSSYFJWOCVCQJJ-UHFFFAOYSA-N benzyl 4-iodobenzoate Chemical compound C1=CC(I)=CC=C1C(=O)OCC1=CC=CC=C1 MSSYFJWOCVCQJJ-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000004305 biphenyl Chemical group 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 206010006060 bowenoid papulosis Diseases 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 229940045348 brown mixture Drugs 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- WEPUZBYKXNKSDH-UHFFFAOYSA-N cyclopentanecarbonyl chloride Chemical compound ClC(=O)C1CCCC1 WEPUZBYKXNKSDH-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- PIZLBWGMERQCOC-UHFFFAOYSA-N dibenzyl carbonate Chemical group C=1C=CC=CC=1COC(=O)OCC1=CC=CC=C1 PIZLBWGMERQCOC-UHFFFAOYSA-N 0.000 description 1
- IRUNKQSGDBYUDC-UHFFFAOYSA-N diethoxymethyl acetate Chemical compound CCOC(OCC)OC(C)=O IRUNKQSGDBYUDC-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 125000006232 ethoxy propyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- IAWCIZWLKMTPLL-UHFFFAOYSA-N fluoroethyne Chemical compound FC#C IAWCIZWLKMTPLL-UHFFFAOYSA-N 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 description 1
- 125000005224 heteroarylcarbonylamino group Chemical group 0.000 description 1
- 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 description 1
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 description 1
- 125000005419 heteroarylsulfonylamino group Chemical group 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- RVMFDSHMPBPWRK-UHFFFAOYSA-N oxolane-3-carbonyl chloride Chemical compound ClC(=O)C1CCOC1 RVMFDSHMPBPWRK-UHFFFAOYSA-N 0.000 description 1
- 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 description 1
- IZGYIFFQBZWOLJ-CKAACLRMSA-N phaseic acid Chemical compound C1C(=O)C[C@@]2(C)OC[C@]1(C)[C@@]2(O)C=CC(/C)=C\C(O)=O IZGYIFFQBZWOLJ-CKAACLRMSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- YGTXEOIHUWEJAR-UHFFFAOYSA-N prop-1-ynyl benzoate Chemical compound CC#COC(=O)C1=CC=CC=C1 YGTXEOIHUWEJAR-UHFFFAOYSA-N 0.000 description 1
- 229940090181 propyl acetate Drugs 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- WKWLANFUFVNHIM-UHFFFAOYSA-N tert-butyl n-[1-[2-[3-[4-(dimethylamino)phenyl]prop-2-ynoxy]ethyl]imidazo[4,5-c]quinolin-4-yl]carbamate Chemical compound C1=CC(N(C)C)=CC=C1C#CCOCCN1C2=C3C=CC=CC3=NC(NC(=O)OC(C)(C)C)=C2N=C1 WKWLANFUFVNHIM-UHFFFAOYSA-N 0.000 description 1
- AHWYBRANSBBZHM-UHFFFAOYSA-N tert-butyl n-[1-[2-[3-[4-(dimethylamino)phenyl]propoxy]ethyl]imidazo[4,5-c]quinolin-4-yl]carbamate Chemical compound C1=CC(N(C)C)=CC=C1CCCOCCN1C2=C3C=CC=CC3=NC(NC(=O)OC(C)(C)C)=C2N=C1 AHWYBRANSBBZHM-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- LBUJPTNKIBCYBY-UHFFFAOYSA-N tetrahydroquinoline Natural products C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000029069 type 2 immune response Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25421800P | 2000-12-08 | 2000-12-08 | |
| PCT/US2001/046581 WO2002046189A2 (en) | 2000-12-08 | 2001-12-06 | Aryl ether substituted imidazoquinolines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK6842003A3 true SK6842003A3 (en) | 2003-12-02 |
Family
ID=22963391
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK715-2003A SK7152003A3 (en) | 2000-12-08 | 2001-12-06 | Heterocyclic ether substituted imidazoquinolines |
| SK712-2003A SK7122003A3 (en) | 2000-12-08 | 2001-12-06 | Urea substituted imidazoquinoline ethers |
| SK710-2003A SK287264B6 (sk) | 2000-12-08 | 2001-12-06 | Deriváty imidazochinolínu a tetrahydroimidazochinolínu, farmaceutické kompozície s ich obsahom a ich použitie |
| SK713-2003A SK287732B6 (en) | 2000-12-08 | 2001-12-06 | Amido ether substituted imidazoquinolines, pharmaceutical composition and use thereof |
| SK711-2003A SK7112003A3 (en) | 2000-12-08 | 2001-12-06 | Sulfonamido ether substituted imidazoquinolines |
| SK684-2003A SK6842003A3 (en) | 2000-12-08 | 2001-12-06 | Aryl ether substituted imidazoquinolines |
Family Applications Before (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK715-2003A SK7152003A3 (en) | 2000-12-08 | 2001-12-06 | Heterocyclic ether substituted imidazoquinolines |
| SK712-2003A SK7122003A3 (en) | 2000-12-08 | 2001-12-06 | Urea substituted imidazoquinoline ethers |
| SK710-2003A SK287264B6 (sk) | 2000-12-08 | 2001-12-06 | Deriváty imidazochinolínu a tetrahydroimidazochinolínu, farmaceutické kompozície s ich obsahom a ich použitie |
| SK713-2003A SK287732B6 (en) | 2000-12-08 | 2001-12-06 | Amido ether substituted imidazoquinolines, pharmaceutical composition and use thereof |
| SK711-2003A SK7112003A3 (en) | 2000-12-08 | 2001-12-06 | Sulfonamido ether substituted imidazoquinolines |
Country Status (31)
| Country | Link |
|---|---|
| US (8) | US6683088B2 (enExample) |
| EP (6) | EP1341791B1 (enExample) |
| JP (7) | JP2004529078A (enExample) |
| KR (6) | KR20030070049A (enExample) |
| CN (6) | CN1894244A (enExample) |
| AR (6) | AR035665A1 (enExample) |
| AT (3) | ATE296301T1 (enExample) |
| AU (12) | AU2002230618B2 (enExample) |
| BR (6) | BR0116052A (enExample) |
| CA (6) | CA2436980C (enExample) |
| CY (2) | CY1105586T1 (enExample) |
| CZ (6) | CZ295848B6 (enExample) |
| DE (3) | DE60111076T2 (enExample) |
| DK (3) | DK1341790T3 (enExample) |
| EE (6) | EE200300268A (enExample) |
| ES (3) | ES2242782T3 (enExample) |
| HR (6) | HRP20030464A2 (enExample) |
| HU (6) | HUP0600338A2 (enExample) |
| IL (6) | IL155903A0 (enExample) |
| MX (6) | MXPA03005011A (enExample) |
| NO (6) | NO20032452L (enExample) |
| NZ (6) | NZ526088A (enExample) |
| PL (7) | PL365995A1 (enExample) |
| PT (2) | PT1341790E (enExample) |
| RU (6) | RU2308456C2 (enExample) |
| SI (1) | SI1341790T1 (enExample) |
| SK (6) | SK7152003A3 (enExample) |
| TW (3) | TWI293300B (enExample) |
| UA (2) | UA75622C2 (enExample) |
| WO (6) | WO2002046193A2 (enExample) |
| ZA (6) | ZA200305273B (enExample) |
Families Citing this family (209)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5741908A (en) | 1996-06-21 | 1998-04-21 | Minnesota Mining And Manufacturing Company | Process for reparing imidazoquinolinamines |
| UA67760C2 (uk) * | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки |
| US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| US6756382B2 (en) | 1999-06-10 | 2004-06-29 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
| US6541485B1 (en) | 1999-06-10 | 2003-04-01 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
| US6573273B1 (en) * | 1999-06-10 | 2003-06-03 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
| US6916925B1 (en) | 1999-11-05 | 2005-07-12 | 3M Innovative Properties Co. | Dye labeled imidazoquinoline compounds |
| JP3436512B2 (ja) * | 1999-12-28 | 2003-08-11 | 株式会社デンソー | アクセル装置 |
| US6667312B2 (en) | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| US6545017B1 (en) | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Urea substituted imidazopyridines |
| US6660747B2 (en) * | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
| US6677347B2 (en) * | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
| US6664265B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
| US6664264B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| US6545016B1 (en) | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Amide substituted imidazopyridines |
| US6660735B2 (en) * | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
| UA75622C2 (en) | 2000-12-08 | 2006-05-15 | 3M Innovative Properties Co | Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon |
| US6677348B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
| US6525064B1 (en) | 2000-12-08 | 2003-02-25 | 3M Innovative Properties Company | Sulfonamido substituted imidazopyridines |
| US7226928B2 (en) * | 2001-06-15 | 2007-06-05 | 3M Innovative Properties Company | Methods for the treatment of periodontal disease |
| EP1450804B9 (en) * | 2001-11-29 | 2009-04-01 | 3M Innovative Properties Company | Pharmaceutical formulations comprising an immune response modifier |
| CA2365732A1 (en) | 2001-12-20 | 2003-06-20 | Ibm Canada Limited-Ibm Canada Limitee | Testing measurements |
| US6677349B1 (en) | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| IL147953A (en) | 2002-02-01 | 2008-04-13 | Meir Bialer | Derivatives and pharmaceutical compositions of n-hydroxymethyl tetramethylcyclopropyl- |
| EP1478327B1 (en) * | 2002-02-22 | 2015-04-29 | Meda AB | Method of reducing and treating uvb-induced immunosuppression |
| GB0211649D0 (en) * | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| CA2488801A1 (en) | 2002-06-07 | 2003-12-18 | 3M Innovative Properties Company | Ether substituted imidazopyridines |
| EP1538907A4 (en) * | 2002-07-02 | 2008-12-24 | Southern Res Inst | FTSZ-HEMMER AND ITS USE |
| DK1545597T3 (da) | 2002-08-15 | 2011-01-31 | 3M Innovative Properties Co | Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons |
| US6818650B2 (en) | 2002-09-26 | 2004-11-16 | 3M Innovative Properties Company | 1H-imidazo dimers |
| NZ540826A (en) | 2002-12-20 | 2008-07-31 | 3M Innovative Properties Co | Aryl / hetaryl substituted imidazoquinolines |
| EP2572715A1 (en) | 2002-12-30 | 2013-03-27 | 3M Innovative Properties Company | Immunostimulatory Combinations |
| JP2006517974A (ja) * | 2003-02-13 | 2006-08-03 | スリーエム イノベイティブ プロパティズ カンパニー | Irm化合物およびトル様受容体8に関する方法および組成物 |
| WO2004075865A2 (en) | 2003-02-27 | 2004-09-10 | 3M Innovative Properties Company | Selective modulation of tlr-mediated biological activity |
| CA2517528A1 (en) * | 2003-03-04 | 2004-09-16 | 3M Innovative Properties Company | Prophylactic treatment of uv-induced epidermal neoplasia |
| JP2006519877A (ja) * | 2003-03-07 | 2006-08-31 | スリーエム イノベイティブ プロパティズ カンパニー | 1−アミノ1h−イミダゾキノリン |
| US7163947B2 (en) * | 2003-03-07 | 2007-01-16 | 3M Innovative Properties Company | 1-Amino 1H-imidazoquinolines |
| US7179253B2 (en) | 2003-03-13 | 2007-02-20 | 3M Innovative Properties Company | Method of tattoo removal |
| CA2518282C (en) * | 2003-03-13 | 2012-11-06 | 3M Innovative Properties Company | Methods of improving skin quality |
| JP2006523212A (ja) * | 2003-03-13 | 2006-10-12 | スリーエム イノベイティブ プロパティズ カンパニー | 皮膚病変の診断方法 |
| US20040192585A1 (en) | 2003-03-25 | 2004-09-30 | 3M Innovative Properties Company | Treatment for basal cell carcinoma |
| EP1615665A4 (en) | 2003-04-10 | 2010-10-06 | 3M Innovative Properties Co | DISTRIBUTION OF THE IMMUNE RESPONSE MODIFYING LINKS |
| US20040265351A1 (en) * | 2003-04-10 | 2004-12-30 | Miller Richard L. | Methods and compositions for enhancing immune response |
| US20040214851A1 (en) * | 2003-04-28 | 2004-10-28 | 3M Innovative Properties Company | Compositions and methods for induction of opioid receptors |
| US6943255B2 (en) * | 2003-06-06 | 2005-09-13 | 3M Innovative Properties Company | Process for imidazo[4,5-c]pyridin-4-amines |
| WO2004110992A2 (en) * | 2003-06-06 | 2004-12-23 | 3M Innovative Properties Company | Process for imidazo[4,5-c] pyridin-4-amines |
| AU2004264336B2 (en) * | 2003-08-05 | 2010-12-23 | 3M Innovative Properties Company | Formulations containing an immune response modifier |
| AU2004266641A1 (en) | 2003-08-12 | 2005-03-03 | 3M Innovative Properties Company | Oxime substituted imidazo-containing compounds |
| WO2005018555A2 (en) | 2003-08-14 | 2005-03-03 | 3M Innovative Properties Company | Lipid-modified immune response modifiers |
| ES2545826T3 (es) * | 2003-08-14 | 2015-09-16 | 3M Innovative Properties Company | Modificadores de la respuesta inmune modificados con lípidos |
| CA2536249A1 (en) | 2003-08-25 | 2005-03-10 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
| CA2551075A1 (en) * | 2003-08-25 | 2005-03-03 | 3M Innovative Properties Company | Immunostimulatory combinations and treatments |
| EP1658076B1 (en) * | 2003-08-27 | 2013-03-06 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted imidazoquinolines |
| MXPA06002408A (es) * | 2003-09-02 | 2006-06-20 | 3M Innovative Properties Co | Metodos relacionados al tratamiento de condiciones asociadas a la mucosa. |
| US20050054665A1 (en) * | 2003-09-05 | 2005-03-10 | 3M Innovative Properties Company | Treatment for CD5+ B cell lymphoma |
| EP1664342A4 (en) * | 2003-09-17 | 2007-12-26 | 3M Innovative Properties Co | SELECTIVE MODULATION OF TLR GENE EXPRESSION |
| US20090075980A1 (en) * | 2003-10-03 | 2009-03-19 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and Analogs Thereof |
| ES2544477T3 (es) * | 2003-10-03 | 2015-08-31 | 3M Innovative Properties Company | Imidazoquinolinas sustituidas con alcoxi |
| KR20060120069A (ko) | 2003-10-03 | 2006-11-24 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 피라졸로피리딘 및 그의 유사체 |
| US7544697B2 (en) * | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
| JP2007509987A (ja) * | 2003-10-31 | 2007-04-19 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫応答調節剤化合物による好中球活性化 |
| JP2007511535A (ja) | 2003-11-14 | 2007-05-10 | スリーエム イノベイティブ プロパティズ カンパニー | ヒドロキシルアミン置換イミダゾ環化合物 |
| US7897767B2 (en) * | 2003-11-14 | 2011-03-01 | 3M Innovative Properties Company | Oxime substituted imidazoquinolines |
| PT1687305E (pt) * | 2003-11-21 | 2008-10-17 | Novartis Ag | Derivados de 1h-imidazoquinolina como inibidores de proteína quinase |
| AR046845A1 (es) * | 2003-11-21 | 2005-12-28 | Novartis Ag | Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas |
| CA2547085A1 (en) * | 2003-11-25 | 2005-06-09 | 3M Innovative Properties Company | Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
| RU2409576C2 (ru) | 2003-11-25 | 2011-01-20 | 3М Инновейтив Пропертиз Компани | Системы, содержащие имидазольное кольцо с заместителями, и способы их получения |
| US8940755B2 (en) * | 2003-12-02 | 2015-01-27 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
| CA2549216A1 (en) * | 2003-12-04 | 2005-08-25 | 3M Innovative Properties Company | Sulfone substituted imidazo ring ethers |
| EP1699792A1 (en) * | 2003-12-29 | 2006-09-13 | 3M Innovative Properties Company | Piperazine, 1,4¨diazepane, 1,4¨diazocane, and 1,5¨diazocane fused imidazo ring compounds |
| WO2005066170A1 (en) | 2003-12-29 | 2005-07-21 | 3M Innovative Properties Company | Arylalkenyl and arylalkynyl substituted imidazoquinolines |
| US20050239735A1 (en) * | 2003-12-30 | 2005-10-27 | 3M Innovative Properties Company | Enhancement of immune responses |
| US20050158325A1 (en) * | 2003-12-30 | 2005-07-21 | 3M Innovative Properties Company | Immunomodulatory combinations |
| CA2551399A1 (en) * | 2003-12-30 | 2005-07-21 | 3M Innovative Properties Company | Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides |
| WO2005089317A2 (en) | 2004-03-15 | 2005-09-29 | 3M Innovative Properties Company | Immune response modifier formulations and methods |
| EP1730143A2 (en) * | 2004-03-24 | 2006-12-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
| EP1735010A4 (en) * | 2004-04-09 | 2008-08-27 | 3M Innovative Properties Co | METHODS, COMPOSITIONS AND PREPARATIONS FOR ADMINISTRATION OF IMMUNE RESPONSE MODIFIERS (MRI) |
| US20050267145A1 (en) * | 2004-05-28 | 2005-12-01 | Merrill Bryon A | Treatment for lung cancer |
| WO2005123079A2 (en) * | 2004-06-14 | 2005-12-29 | 3M Innovative Properties Company | Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
| WO2005123080A2 (en) * | 2004-06-15 | 2005-12-29 | 3M Innovative Properties Company | Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
| US7884207B2 (en) * | 2004-06-18 | 2011-02-08 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
| US8541438B2 (en) | 2004-06-18 | 2013-09-24 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
| WO2006009826A1 (en) * | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
| WO2006065280A2 (en) | 2004-06-18 | 2006-06-22 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods |
| WO2006038923A2 (en) | 2004-06-18 | 2006-04-13 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
| US20070259881A1 (en) * | 2004-06-18 | 2007-11-08 | Dellaria Joseph F Jr | Substituted Imidazo Ring Systems and Methods |
| CA2578975A1 (en) | 2004-09-02 | 2006-03-16 | 3M Innovative Properties Company | 2-amino 1h imidazo ring systems and methods |
| PL1789042T3 (pl) * | 2004-09-02 | 2012-09-28 | 3M Innovative Properties Co | Układy pierścieni 1-alkoksy 1H-imidazo i sposoby |
| US20090270443A1 (en) * | 2004-09-02 | 2009-10-29 | Doris Stoermer | 1-amino imidazo-containing compounds and methods |
| US20080193468A1 (en) * | 2004-09-08 | 2008-08-14 | Children's Medical Center Corporation | Method for Stimulating the Immune Response of Newborns |
| BRPI0515316A (pt) * | 2004-09-14 | 2008-07-15 | Chiron Corp | compostos de imidazoquinolina |
| US20070243215A1 (en) * | 2004-10-08 | 2007-10-18 | Miller Richard L | Adjuvant for Dna Vaccines |
| EP1819364A4 (en) * | 2004-12-08 | 2010-12-29 | 3M Innovative Properties Co | COMPOSITIONS, IMMUNOMODULATORY COMBINATIONS AND ASSOCIATED METHODS |
| US8080560B2 (en) * | 2004-12-17 | 2011-12-20 | 3M Innovative Properties Company | Immune response modifier formulations containing oleic acid and methods |
| US8461174B2 (en) | 2004-12-30 | 2013-06-11 | 3M Innovative Properties Company | Treatment for cutaneous metastases |
| NZ556399A (en) * | 2004-12-30 | 2009-03-31 | Takeda Pharmaceutical | 1-(2-methylpropyl)-1H-imidazo[4,5-C][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1H-imidazo[4,5-C][1,5]naphthyridin-4-amine methanesulfonate |
| AU2005326708C1 (en) | 2004-12-30 | 2012-08-30 | 3M Innovative Properties Company | Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds |
| CA2592904C (en) | 2004-12-30 | 2015-04-07 | 3M Innovative Properties Company | Chiral fused [1,2]imidazo[4,5-c] ring compounds |
| US8436176B2 (en) * | 2004-12-30 | 2013-05-07 | Medicis Pharmaceutical Corporation | Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine |
| US9248127B2 (en) | 2005-02-04 | 2016-02-02 | 3M Innovative Properties Company | Aqueous gel formulations containing immune response modifiers |
| WO2006086449A2 (en) * | 2005-02-09 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines |
| JP2008530252A (ja) | 2005-02-09 | 2008-08-07 | コーリー ファーマシューティカル グループ,インコーポレイテッド | オキシムおよびヒドロキシルアミンで置換されたチアゾロ[4,5−c]環化合物ならびに方法 |
| WO2006086634A2 (en) | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods |
| WO2006091394A2 (en) * | 2005-02-11 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Substituted imidazoquinolines and imidazonaphthyridines |
| US8062644B2 (en) | 2005-02-18 | 2011-11-22 | Novartis Vaccines & Diagnostics Srl. | Immunogens from uropathogenic Escherichia coli |
| ES2595363T3 (es) | 2005-02-18 | 2016-12-29 | J. Craig Venter Institute, Inc. | Sepsis asociada a las proteínas y los ácidos nucleicos de meningitis / Escherichia coli |
| JP2008538203A (ja) * | 2005-02-23 | 2008-10-16 | コーリー ファーマシューティカル グループ,インコーポレイテッド | インターフェロンの生合成を優先的に誘導する方法 |
| EP1851220A2 (en) | 2005-02-23 | 2007-11-07 | 3M Innovative Properties Company | Hydroxyalkyl substituted imidazonaphthyridines |
| WO2006098852A2 (en) | 2005-02-23 | 2006-09-21 | Coley Pharmaceutical Group, Inc. | Hydroxyalkyl substituted imidazoquinolines |
| EP1851218A2 (en) | 2005-02-23 | 2007-11-07 | 3M Innovative Properties Company | Hydroxyalkyl substituted imidazoquinoline compounds and methods |
| AU2006223148A1 (en) | 2005-03-14 | 2006-09-21 | 3M Innovative Properties Company | Method of treating actinic keratosis |
| AU2006232375A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
| US7943610B2 (en) | 2005-04-01 | 2011-05-17 | 3M Innovative Properties Company | Pyrazolopyridine-1,4-diamines and analogs thereof |
| JP2008539252A (ja) * | 2005-04-25 | 2008-11-13 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫活性化組成物 |
| WO2007011777A2 (en) | 2005-07-18 | 2007-01-25 | Novartis Ag | Small animal model for hcv replication |
| EA200800782A1 (ru) | 2005-09-09 | 2008-08-29 | Коли Фармасьютикал Груп, Инк. | ПРОИЗВОДНЫЕ АМИДА И КАРБАМАТА N-{2-[4-АМИНО-2-(ЭТОКСИМЕТИЛ)-1Н-ИМИДАЗОЛО[4,5-c]ХИНОЛИН-1-IL]-1,1-ДИМЕТИЛЭТИЛ}МЕТАНСУЛЬФОНАМИДА И СПОСОБЫ |
| ZA200803029B (en) | 2005-09-09 | 2009-02-25 | Coley Pharm Group Inc | Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods |
| US8889154B2 (en) | 2005-09-15 | 2014-11-18 | Medicis Pharmaceutical Corporation | Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation |
| AU2006310163B2 (en) | 2005-11-04 | 2011-09-15 | Seqirus UK Limited | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
| WO2007052058A1 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
| HUE051122T2 (hu) | 2005-11-04 | 2021-03-01 | Seqirus Uk Ltd | Sejttenyészetben növesztett influenzavírusból elõállított nemvirion anti-géneket tartalmazó adjuvált vakcinák |
| NZ592713A (en) | 2005-11-04 | 2012-12-21 | Novartis Vaccines & Diagnostic | Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9 |
| WO2007056112A2 (en) * | 2005-11-04 | 2007-05-18 | Coley Pharmaceutical Group, Inc. | Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods |
| HUE049580T2 (hu) | 2006-01-27 | 2020-09-28 | Seqirus Uk Ltd | Hemagglutinint és mátrixfehérjéket tartalmazó, influenza elleni oltóanyagok |
| WO2007100634A2 (en) | 2006-02-22 | 2007-09-07 | 3M Innovative Properties Company | Immune response modifier conjugates |
| US8329721B2 (en) * | 2006-03-15 | 2012-12-11 | 3M Innovative Properties Company | Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods |
| WO2007109810A2 (en) * | 2006-03-23 | 2007-09-27 | Novartis Ag | Methods for the preparation of imidazole-containing compounds |
| CA2646539A1 (en) * | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
| EP2007765B1 (en) * | 2006-03-23 | 2012-06-27 | Novartis AG | Immunopotentiating compounds |
| CN101448523A (zh) | 2006-03-24 | 2009-06-03 | 诺华疫苗和诊断有限两合公司 | 无需冷藏储存流感疫苗 |
| US20100285062A1 (en) | 2006-03-31 | 2010-11-11 | Novartis Ag | Combined mucosal and parenteral immunization against hiv |
| WO2008020335A2 (en) | 2006-06-09 | 2008-02-21 | Novartis Ag | Immunogenic compositions for streptococcus agalactiae |
| US7906506B2 (en) | 2006-07-12 | 2011-03-15 | 3M Innovative Properties Company | Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods |
| GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
| WO2008020330A2 (en) | 2006-08-16 | 2008-02-21 | Novartis Ag | Immunogens from uropathogenic escherichia coli |
| WO2008030511A2 (en) | 2006-09-06 | 2008-03-13 | Coley Pharmaceuticial Group, Inc. | Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes |
| EP4585610A3 (en) | 2006-09-11 | 2025-09-24 | Seqirus UK Limited | Making influenza virus vaccines without using eggs |
| PL2121011T3 (pl) | 2006-12-06 | 2014-10-31 | Novartis Ag | Szczepionki zawierające antygeny czterech szczepów wirusa grypy |
| US20080149123A1 (en) * | 2006-12-22 | 2008-06-26 | Mckay William D | Particulate material dispensing hairbrush with combination bristles |
| GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
| CN101784283A (zh) | 2007-06-27 | 2010-07-21 | 诺华有限公司 | 低添加流感疫苗 |
| GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
| CN101909624A (zh) * | 2008-01-15 | 2010-12-08 | 麦达股份公司 | 用咪唑并喹啉衍生物治疗结肠病或预防结肠直肠癌 |
| PL2268618T3 (pl) * | 2008-03-03 | 2015-11-30 | Novartis Ag | Związki i kompozycje jako modulatory aktywności receptorów TLR |
| EA201071086A1 (ru) | 2008-03-18 | 2011-04-29 | Новартис Аг | Усовершенствованный способ получения вакцинных антигенов вируса гриппа |
| US8568732B2 (en) | 2009-03-06 | 2013-10-29 | Novartis Ag | Chlamydia antigens |
| MX2011010050A (es) | 2009-03-25 | 2011-12-14 | Univ Texas | Composiciones para estimulación de resistencia inmune innata de mamiferos a patógenos. |
| CA2758490C (en) | 2009-04-14 | 2023-05-02 | Novartis Ag | Compositions for immunising against staphylococcus aureus |
| CN102548577A (zh) | 2009-04-27 | 2012-07-04 | 诺华有限公司 | 用于抵抗流感的佐剂疫苗 |
| GB0907551D0 (en) * | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| AU2013203591B2 (en) * | 2009-05-01 | 2017-01-19 | University Court Of The University Of Dundee | Treatment or prophylaxis of proliferative conditions |
| SI3178490T1 (sl) | 2009-07-15 | 2022-08-31 | Glaxosmithkline Biologicals S.A. | Sestavki proteina F RSV-ja in postopki za pripravo le-teh |
| HRP20141270T1 (xx) | 2009-07-16 | 2015-03-13 | Novartis Ag | Detoksificirani imunogeni escherichie coli |
| GB0918392D0 (en) | 2009-10-20 | 2009-12-02 | Novartis Ag | Diagnostic and therapeutic methods |
| GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
| GB201009861D0 (en) | 2010-06-11 | 2010-07-21 | Novartis Ag | OMV vaccines |
| HRP20170433T1 (hr) | 2010-08-17 | 2017-05-05 | 3M Innovative Properties Company | Pripravci spoja za izmjenu lipidiranog imunološkog odgovora, formulacije, i postupci |
| WO2012080728A1 (en) | 2010-12-16 | 2012-06-21 | Astrazeneca Ab | Imidazo [4, 5 -c] quinolin- 1 -yl derivative useful in therapy |
| HRP20190791T1 (hr) | 2011-01-26 | 2019-06-28 | Glaxosmithkline Biologicals Sa | Režim imuniziranja protiv rsv |
| SI3275892T1 (sl) | 2011-05-13 | 2020-06-30 | Glaxosmithkline Biologicals S.A. | Prefuzijski RSV F antigeni |
| US8728486B2 (en) | 2011-05-18 | 2014-05-20 | University Of Kansas | Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds |
| WO2012167081A1 (en) | 2011-06-03 | 2012-12-06 | 3M Innovative Properties Company | Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom |
| CN103582496B (zh) | 2011-06-03 | 2016-05-11 | 3M创新有限公司 | 具有聚乙二醇链段的异双官能连接基以及由其制成的免疫应答调节剂缀合物 |
| US20130023736A1 (en) | 2011-07-21 | 2013-01-24 | Stanley Dale Harpstead | Systems for drug delivery and monitoring |
| JP6170932B2 (ja) | 2011-11-07 | 2017-07-26 | ノバルティス アーゲー | spr0096抗原およびspr2021抗原を含むキャリア分子 |
| WO2013108272A2 (en) | 2012-01-20 | 2013-07-25 | International Centre For Genetic Engineering And Biotechnology | Blood stage malaria vaccine |
| CN103566377A (zh) | 2012-07-18 | 2014-02-12 | 上海博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| CN105025854A (zh) | 2013-01-07 | 2015-11-04 | 宾夕法尼亚大学董事会 | 治疗皮肤t细胞淋巴瘤的组合物和方法 |
| ES3020582T3 (en) | 2013-07-26 | 2025-05-23 | Inst Nat Sante Rech Med | Methods and pharmaceutical compositions for the treatment of bacterial infections |
| CR20160214A (es) | 2013-11-05 | 2016-10-11 | 3M Innovative Properties Co | Formulaciones de inyección con base en aceite de sésamo |
| EP2870974A1 (en) | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella conjugate vaccines |
| CA2936377A1 (en) | 2014-01-10 | 2015-07-16 | Shanghai Birdie Biotech, Inc. | Compounds and compositions for treating egfr expressing tumors |
| EP3122378B1 (en) | 2014-03-26 | 2019-12-11 | GlaxoSmithKline Biologicals S.A. | Mutant staphylococcal antigens |
| EP4001311B1 (en) | 2014-07-09 | 2025-11-05 | Birdie Biopharmaceuticals Inc. | Anti-pd-l1/pd-1 combinations for treating tumors |
| CN112546231A (zh) | 2014-07-09 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
| CN105461767B (zh) * | 2014-08-07 | 2019-03-12 | 富力 | 一种连翘苷的化学合成方法 |
| CN112546238A (zh) | 2014-09-01 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| WO2016044839A2 (en) | 2014-09-19 | 2016-03-24 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
| EP3350178B1 (en) * | 2015-09-14 | 2021-10-20 | Pfizer Inc. | Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors |
| EP3356371A4 (en) * | 2015-09-29 | 2020-06-24 | The University of Chicago | POLYMER CONJUGATE VACCINES |
| US10526309B2 (en) | 2015-10-02 | 2020-01-07 | The University Of North Carolina At Chapel Hill | Pan-TAM inhibitors and Mer/Axl dual inhibitors |
| CN115350279A (zh) | 2016-01-07 | 2022-11-18 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-her2组合 |
| CN115252792A (zh) | 2016-01-07 | 2022-11-01 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| CN115554406A (zh) | 2016-01-07 | 2023-01-03 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-cd20组合 |
| BR112019009469A2 (pt) | 2016-11-09 | 2019-07-30 | Pulmotect Inc | métodos e composições para a modulação imunológica adaptativa |
| CN118515666A (zh) | 2017-04-27 | 2024-08-20 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
| CA3067268A1 (en) | 2017-06-23 | 2018-12-27 | Birdie Biopharmaceuticals, Inc. | Crystalline resiquimod monosulfate anhydrate and its preparation and uses |
| EP3728255B1 (en) | 2017-12-20 | 2022-01-26 | 3M Innovative Properties Company | Amide substituted imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier |
| AU2019216531A1 (en) | 2018-02-02 | 2020-09-24 | Maverix Oncology, Inc. | Small molecule drug conjugates of gemcitabine monophosphate |
| KR20200128116A (ko) | 2018-02-28 | 2020-11-11 | 화이자 인코포레이티드 | Il-15 변이체 및 이의 용도 |
| CA3092545A1 (en) * | 2018-02-28 | 2019-09-06 | 3M Innovative Properties Company | Substituted imidazo[4,5-c]quinoline compounds with an n-1 branched group |
| KR20230146098A (ko) | 2018-05-23 | 2023-10-18 | 화이자 인코포레이티드 | GUCY2c에 특이적인 항체 및 이의 용도 |
| DK3797121T3 (da) | 2018-05-23 | 2024-07-08 | Pfizer | Antistoffer, der er specifikke for CD3, og anvendelser deraf |
| EP3802536B1 (en) * | 2018-05-24 | 2022-07-13 | 3M Innovative Properties Company | N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods |
| CA3107305A1 (en) * | 2018-07-24 | 2020-01-30 | Torque Therapeutics, Inc. | Tlr7/8 agonists and liposome compositions |
| WO2020109898A1 (en) * | 2018-11-26 | 2020-06-04 | 3M Innovative Properties Company | N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods |
| WO2020128893A1 (en) | 2018-12-21 | 2020-06-25 | Pfizer Inc. | Combination treatments of cancer comprising a tlr agonist |
| WO2020163118A1 (en) * | 2019-02-07 | 2020-08-13 | Canwell Biotech Limited | Phosphorus imidazoquinoline amine derivatives, pharmaceutical compositions and therapeutic methods thereof |
| US20220226488A1 (en) | 2019-02-12 | 2022-07-21 | Ambrx, Inc. | Compositions containing, methods and uses of antibody-tlr agonist conjugates |
| CN113614083B (zh) | 2019-03-27 | 2024-08-27 | 默克专利股份公司 | 咪唑酮基喹啉化合物及其治疗用途 |
| EP4051270A4 (en) * | 2019-10-29 | 2024-02-28 | Prime Reach Trading Limited | 4-AMINO-IMODAZOCINOLINE COMPOUNDS AND USES THEREOF |
| WO2021116420A1 (en) | 2019-12-13 | 2021-06-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of tlr7 and/or tlr8 agonists for the treatment of leptospirosis |
| PE20230160A1 (es) | 2019-12-17 | 2023-02-01 | Pfizer | Anticuerpos especificos para cd47, pd-l1 y sus usos |
| JP2023533793A (ja) | 2020-07-17 | 2023-08-04 | ファイザー・インク | 治療用抗体およびそれらの使用 |
| JP2023538071A (ja) | 2020-08-20 | 2023-09-06 | アンブルックス,インコーポレイテッド | 抗体-tlrアゴニストコンジュゲート、その方法及び使用 |
| JP2023554377A (ja) * | 2020-12-16 | 2023-12-27 | スリーエム イノベイティブ プロパティズ カンパニー | N-1分岐イミダゾキノリン、そのコンジュゲート、及び方法 |
| WO2025104289A1 (en) | 2023-11-17 | 2025-05-22 | Medincell S.A. | Antineoplastic combinations |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2135210A (en) * | 1937-03-13 | 1938-11-01 | John R Farrar | Golf ball |
| US3314941A (en) | 1964-06-23 | 1967-04-18 | American Cyanamid Co | Novel substituted pyridodiazepins |
| US3692907A (en) * | 1970-10-27 | 1972-09-19 | Richardson Merrell Inc | Treating viral infections with bis-basic ethers and thioethers of fluorenone and fluorene and pharmaceutical compositons of the same |
| US3819190A (en) * | 1972-10-02 | 1974-06-25 | D Nepela | Golf ball |
| US4284276A (en) * | 1980-02-13 | 1981-08-18 | Worst Joseph C | Grooved golf ball |
| ZA848968B (en) | 1983-11-18 | 1986-06-25 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines |
| CA1271477A (en) * | 1983-11-18 | 1990-07-10 | John F. Gerster | 1h-imidazo[4,5-c]quinolin-4-amines |
| IL73534A (en) * | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| JPH0327380Y2 (enExample) | 1985-05-22 | 1991-06-13 | ||
| US4880779A (en) * | 1987-07-31 | 1989-11-14 | Research Corporation Technologies, Inc. | Method of prevention or treatment of AIDS by inhibition of human immunodeficiency virus |
| US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
| EP0385630B1 (en) | 1989-02-27 | 1996-11-27 | Riker Laboratories, Inc. | 1H-imidazo(4,5-c)Quinolin-4-amines as antivirals |
| US5756747A (en) | 1989-02-27 | 1998-05-26 | Riker Laboratories, Inc. | 1H-imidazo 4,5-c!quinolin-4-amines |
| US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
| US5037986A (en) | 1989-03-23 | 1991-08-06 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo[4,5-c]quinolin-4-amines |
| NZ232740A (en) | 1989-04-20 | 1992-06-25 | Riker Laboratories Inc | Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster |
| US4988815A (en) * | 1989-10-26 | 1991-01-29 | Riker Laboratories, Inc. | 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines |
| US5054153A (en) * | 1989-12-01 | 1991-10-08 | Silliman Paul D | Golf club cleaner |
| ATE121088T1 (de) | 1990-10-05 | 1995-04-15 | Minnesota Mining & Mfg | Verfahren zur herstellung von imidazo(4,5- c>chinolin-4-aminen. |
| US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| HU222251B1 (hu) | 1991-03-01 | 2003-05-28 | Minnesota Mining And Manufacturing Company | 1-és 2-helyzetben szubsztituált 1H-imidazo[4,5-c]kinolin-4-amin-származékok előállításában alkalmazható 1- és 2-helyzetben szubsztituált 1H-imidazo[4,5-c]kinolin-4-(szubsztituált)-származékok |
| US5175296A (en) | 1991-03-01 | 1992-12-29 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-c]quinolin-4-amines and processes for their preparation |
| US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| PH31245A (en) * | 1991-10-30 | 1998-06-18 | Janssen Pharmaceutica Nv | 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives. |
| US5266575A (en) * | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
| IL105325A (en) | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
| FR2692159B1 (fr) * | 1992-06-10 | 1996-10-11 | Vartan Berberian | Boule pour jeux de boules et procedes d'obtention d'une telle boule. |
| US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
| US5648516A (en) | 1994-07-20 | 1997-07-15 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
| US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
| CA2167042A1 (en) | 1993-07-15 | 1995-01-26 | Kyle J. Lindstrom | Imidazo[4,5-c]pyridin-4-amines |
| US5644063A (en) | 1994-09-08 | 1997-07-01 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-c]pyridin-4-amine intermediates |
| US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
| JPH09116911A (ja) * | 1995-10-20 | 1997-05-02 | Canon Inc | 撮像システム |
| JPH09208584A (ja) | 1996-01-29 | 1997-08-12 | Terumo Corp | アミド誘導体、およびそれを含有する医薬製剤、および合成中間体 |
| JPH09255926A (ja) | 1996-03-26 | 1997-09-30 | Diatex Co Ltd | 粘着テープ |
| US5741908A (en) | 1996-06-21 | 1998-04-21 | Minnesota Mining And Manufacturing Company | Process for reparing imidazoquinolinamines |
| US5693811A (en) | 1996-06-21 | 1997-12-02 | Minnesota Mining And Manufacturing Company | Process for preparing tetrahdroimidazoquinolinamines |
| US5759109A (en) * | 1996-09-09 | 1998-06-02 | Martini; Byron Rocco | Simulated golf ball instructional device |
| CZ294563B6 (cs) * | 1996-10-25 | 2005-02-16 | Minnesota Mining And Manufacturing Company | Sloučeniny představující modifikátory imunitní odezvy při léčení nemocí mediovaných TH2 buňkami a nemocí odvozených |
| US5939090A (en) | 1996-12-03 | 1999-08-17 | 3M Innovative Properties Company | Gel formulations for topical drug delivery |
| US6069149A (en) | 1997-01-09 | 2000-05-30 | Terumo Kabushiki Kaisha | Amide derivatives and intermediates for the synthesis thereof |
| UA67760C2 (uk) | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки |
| JPH11222432A (ja) | 1998-02-03 | 1999-08-17 | Terumo Corp | インターフェロンを誘起するアミド誘導体を含有する外用剤 |
| JPH11255926A (ja) | 1998-03-13 | 1999-09-21 | Toray Ind Inc | シリコーン成型品およびその製造方法 |
| CN1220997C (zh) * | 1998-05-22 | 2005-09-28 | 松下电器产业株式会社 | 电解电容器及其制造方法 |
| US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| JP2000119271A (ja) | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | 1h―イミダゾピリジン誘導体 |
| SK287112B6 (sk) * | 1999-01-08 | 2009-12-07 | 3M Innovative Properties Company | Použitie zlúčeniny modifikujúcej imunitnú odpoveď pri liečení cervikálnej dysplázie |
| US20020058674A1 (en) | 1999-01-08 | 2002-05-16 | Hedenstrom John C. | Systems and methods for treating a mucosal surface |
| EP1495758A3 (en) | 1999-01-08 | 2005-04-13 | 3M Innovative Properties Company | Formulations and methods for treatment of mucosal associated conditions with an immune response modifier |
| US6558951B1 (en) | 1999-02-11 | 2003-05-06 | 3M Innovative Properties Company | Maturation of dendritic cells with immune response modifying compounds |
| JP2000247884A (ja) | 1999-03-01 | 2000-09-12 | Sumitomo Pharmaceut Co Ltd | アラキドン酸誘発皮膚疾患治療剤 |
| US6756382B2 (en) | 1999-06-10 | 2004-06-29 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
| US6541485B1 (en) | 1999-06-10 | 2003-04-01 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
| US6451810B1 (en) | 1999-06-10 | 2002-09-17 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
| US6573273B1 (en) | 1999-06-10 | 2003-06-03 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
| US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| US6376669B1 (en) | 1999-11-05 | 2002-04-23 | 3M Innovative Properties Company | Dye labeled imidazoquinoline compounds |
| US6894060B2 (en) | 2000-03-30 | 2005-05-17 | 3M Innovative Properties Company | Method for the treatment of dermal lesions caused by envenomation |
| US20020055517A1 (en) | 2000-09-15 | 2002-05-09 | 3M Innovative Properties Company | Methods for delaying recurrence of herpes virus symptoms |
| JP2002145777A (ja) | 2000-11-06 | 2002-05-22 | Sumitomo Pharmaceut Co Ltd | アラキドン酸誘発皮膚疾患治療剤 |
| UA75622C2 (en) | 2000-12-08 | 2006-05-15 | 3M Innovative Properties Co | Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon |
| UA74593C2 (en) | 2000-12-08 | 2006-01-16 | 3M Innovative Properties Co | Substituted imidazopyridines |
| US6660735B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
| US6545017B1 (en) | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Urea substituted imidazopyridines |
| WO2002046749A2 (en) | 2000-12-08 | 2002-06-13 | 3M Innovative Properties Company | Screening method for identifying compounds that selectively induce interferon alpha |
| US6664260B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Heterocyclic ether substituted imidazoquinolines |
| US6667312B2 (en) | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| US6677347B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
| US6664265B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
| US6545016B1 (en) | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Amide substituted imidazopyridines |
| US6525064B1 (en) | 2000-12-08 | 2003-02-25 | 3M Innovative Properties Company | Sulfonamido substituted imidazopyridines |
| US6660747B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
| US6677348B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
| US6664264B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| EP1401437A1 (en) | 2001-06-15 | 2004-03-31 | 3M Innovative Properties Company | Immune response modifiers for the treatment of periodontal disease |
| JP2005501550A (ja) | 2001-08-30 | 2005-01-20 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫反応調整剤分子を用いた形質細胞様樹状細胞を成熟させる方法 |
| EP1478371A4 (en) | 2001-10-12 | 2007-11-07 | Univ Iowa Res Found | METHOD AND PRODUCTS FOR IMPROVING IMMUNE RESPONSES WITH IMIDAZOCHINOLINE COMPOUNDS |
| AU2002343728A1 (en) | 2001-11-16 | 2003-06-10 | 3M Innovative Properties Company | Methods and compositions related to irm compounds and toll-like receptor pathways |
| EP1450804B9 (en) | 2001-11-29 | 2009-04-01 | 3M Innovative Properties Company | Pharmaceutical formulations comprising an immune response modifier |
| US6677349B1 (en) | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| EP1478327B1 (en) | 2002-02-22 | 2015-04-29 | Meda AB | Method of reducing and treating uvb-induced immunosuppression |
| GB0211649D0 (en) | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| WO2003101949A2 (en) | 2002-05-29 | 2003-12-11 | 3M Innovative Properties Company | Process for imidazo[4,5-c]pyridin-4-amines |
| CA2488801A1 (en) | 2002-06-07 | 2003-12-18 | 3M Innovative Properties Company | Ether substituted imidazopyridines |
| DK1545597T3 (da) | 2002-08-15 | 2011-01-31 | 3M Innovative Properties Co | Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons |
| US6818650B2 (en) | 2002-09-26 | 2004-11-16 | 3M Innovative Properties Company | 1H-imidazo dimers |
| AU2003287316A1 (en) | 2002-12-11 | 2004-06-30 | 3M Innovative Properties Company | Assays relating to toll-like receptor activity |
| AU2003287324A1 (en) | 2002-12-11 | 2004-06-30 | 3M Innovative Properties Company | Gene expression systems and recombinant cell lines |
| NZ540826A (en) * | 2002-12-20 | 2008-07-31 | 3M Innovative Properties Co | Aryl / hetaryl substituted imidazoquinolines |
| EP2572715A1 (en) | 2002-12-30 | 2013-03-27 | 3M Innovative Properties Company | Immunostimulatory Combinations |
| JP2006517974A (ja) | 2003-02-13 | 2006-08-03 | スリーエム イノベイティブ プロパティズ カンパニー | Irm化合物およびトル様受容体8に関する方法および組成物 |
| WO2004075865A2 (en) | 2003-02-27 | 2004-09-10 | 3M Innovative Properties Company | Selective modulation of tlr-mediated biological activity |
| CA2517528A1 (en) | 2003-03-04 | 2004-09-16 | 3M Innovative Properties Company | Prophylactic treatment of uv-induced epidermal neoplasia |
| JP2006519877A (ja) | 2003-03-07 | 2006-08-31 | スリーエム イノベイティブ プロパティズ カンパニー | 1−アミノ1h−イミダゾキノリン |
| CA2518282C (en) | 2003-03-13 | 2012-11-06 | 3M Innovative Properties Company | Methods of improving skin quality |
| JP2006523212A (ja) | 2003-03-13 | 2006-10-12 | スリーエム イノベイティブ プロパティズ カンパニー | 皮膚病変の診断方法 |
| US7179253B2 (en) | 2003-03-13 | 2007-02-20 | 3M Innovative Properties Company | Method of tattoo removal |
| US20040192585A1 (en) | 2003-03-25 | 2004-09-30 | 3M Innovative Properties Company | Treatment for basal cell carcinoma |
| EP1613956A2 (en) | 2003-03-25 | 2006-01-11 | 3M Innovative Properties Company | Selective activation of cellular activities mediated through a common toll-like receptor |
| EP1615665A4 (en) | 2003-04-10 | 2010-10-06 | 3M Innovative Properties Co | DISTRIBUTION OF THE IMMUNE RESPONSE MODIFYING LINKS |
| CA2537450C (en) | 2003-09-05 | 2012-04-17 | Anadys Pharmaceuticals, Inc. | Administration of tlr7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus |
-
2001
- 2001-06-12 UA UA2003065277A patent/UA75622C2/uk unknown
- 2001-06-12 UA UA2003065275A patent/UA74852C2/uk unknown
- 2001-12-06 BR BRPI0116052-4A patent/BR0116052A/pt not_active Application Discontinuation
- 2001-12-06 EP EP01987297A patent/EP1341791B1/en not_active Expired - Lifetime
- 2001-12-06 HR HR20030464A patent/HRP20030464A2/hr not_active Application Discontinuation
- 2001-12-06 EE EEP200300268A patent/EE200300268A/xx unknown
- 2001-12-06 HR HR20030461A patent/HRP20030461A2/hr not_active Application Discontinuation
- 2001-12-06 CA CA2436980A patent/CA2436980C/en not_active Expired - Fee Related
- 2001-12-06 PL PL01365995A patent/PL365995A1/xx unknown
- 2001-12-06 NZ NZ526088A patent/NZ526088A/xx unknown
- 2001-12-06 HR HR20030463A patent/HRP20030463A2/xx not_active Application Discontinuation
- 2001-12-06 KR KR10-2003-7007534A patent/KR20030070049A/ko not_active Abandoned
- 2001-12-06 DK DK01987283T patent/DK1341790T3/da active
- 2001-12-06 PT PT01987283T patent/PT1341790E/pt unknown
- 2001-12-06 CZ CZ20031560A patent/CZ295848B6/cs not_active IP Right Cessation
- 2001-12-06 HU HU0600338A patent/HUP0600338A2/hu active IP Right Revival
- 2001-12-06 CN CNA018201725A patent/CN1894244A/zh active Pending
- 2001-12-06 US US10/012,599 patent/US6683088B2/en not_active Expired - Fee Related
- 2001-12-06 JP JP2002547927A patent/JP2004529078A/ja active Pending
- 2001-12-06 PL PL366330A patent/PL207340B1/pl not_active IP Right Cessation
- 2001-12-06 PL PL01365907A patent/PL365907A1/xx not_active Application Discontinuation
- 2001-12-06 NZ NZ526087A patent/NZ526087A/en unknown
- 2001-12-06 JP JP2002547926A patent/JP2004523498A/ja active Pending
- 2001-12-06 HR HR20030462A patent/HRP20030462A2/xx not_active Application Discontinuation
- 2001-12-06 AU AU2002230618A patent/AU2002230618B2/en not_active Ceased
- 2001-12-06 EP EP01987283A patent/EP1341790B1/en not_active Expired - Lifetime
- 2001-12-06 WO PCT/US2001/046704 patent/WO2002046193A2/en not_active Ceased
- 2001-12-06 IL IL15590301A patent/IL155903A0/xx unknown
- 2001-12-06 CA CA002436984A patent/CA2436984A1/en not_active Abandoned
- 2001-12-06 WO PCT/US2001/046359 patent/WO2002046188A2/en not_active Ceased
- 2001-12-06 WO PCT/US2001/046581 patent/WO2002046189A2/en not_active Ceased
- 2001-12-06 PT PT01987297T patent/PT1341791E/pt unknown
- 2001-12-06 PL PL392462A patent/PL392462A1/pl unknown
- 2001-12-06 CZ CZ20031561A patent/CZ20031561A3/cs unknown
- 2001-12-06 AT AT01987297T patent/ATE296301T1/de active
- 2001-12-06 HU HU0600600A patent/HUP0600600A2/hu unknown
- 2001-12-06 HU HU0400710A patent/HUP0400710A2/hu unknown
- 2001-12-06 SK SK715-2003A patent/SK7152003A3/sk unknown
- 2001-12-06 CN CNB01820161XA patent/CN1253452C/zh not_active Expired - Fee Related
- 2001-12-06 AU AU3249702A patent/AU3249702A/xx active Pending
- 2001-12-06 JP JP2002547929A patent/JP2004515500A/ja not_active Withdrawn
- 2001-12-06 ES ES01987297T patent/ES2242782T3/es not_active Expired - Lifetime
- 2001-12-06 HU HU0600605A patent/HUP0600605A2/hu unknown
- 2001-12-06 IL IL15595001A patent/IL155950A0/xx unknown
- 2001-12-06 NZ NZ526105A patent/NZ526105A/en unknown
- 2001-12-06 CN CNA018201687A patent/CN1479739A/zh active Pending
- 2001-12-06 JP JP2002547925A patent/JP4437189B2/ja not_active Expired - Fee Related
- 2001-12-06 DE DE60111076T patent/DE60111076T2/de not_active Expired - Lifetime
- 2001-12-06 IL IL15590401A patent/IL155904A0/xx unknown
- 2001-12-06 IL IL15588401A patent/IL155884A0/xx unknown
- 2001-12-06 EP EP01987282A patent/EP1341789A2/en not_active Ceased
- 2001-12-06 JP JP2002547928A patent/JP2004521092A/ja not_active Ceased
- 2001-12-06 CN CNB018201679A patent/CN1297554C/zh not_active Expired - Fee Related
- 2001-12-06 MX MXPA03005011A patent/MXPA03005011A/es active IP Right Grant
- 2001-12-06 US US10/013,202 patent/US6670372B2/en not_active Expired - Fee Related
- 2001-12-06 MX MXPA03005012A patent/MXPA03005012A/es active IP Right Grant
- 2001-12-06 RU RU2003116059/04A patent/RU2308456C2/ru not_active IP Right Cessation
- 2001-12-06 BR BR0116470-8A patent/BR0116470A/pt not_active IP Right Cessation
- 2001-12-06 HU HU0700062A patent/HUP0700062A2/hu active IP Right Revival
- 2001-12-06 AU AU2002239530A patent/AU2002239530B2/en not_active Ceased
- 2001-12-06 MX MXPA03004975A patent/MXPA03004975A/es active IP Right Grant
- 2001-12-06 RU RU2003116123/04A patent/RU2003116123A/ru not_active Application Discontinuation
- 2001-12-06 EE EEP200300274A patent/EE200300274A/xx unknown
- 2001-12-06 SK SK712-2003A patent/SK7122003A3/sk unknown
- 2001-12-06 DK DK01987297T patent/DK1341791T3/da active
- 2001-12-06 BR BR0116047-8A patent/BR0116047A/pt not_active IP Right Cessation
- 2001-12-06 CN CNB018199070A patent/CN1252070C/zh not_active Expired - Fee Related
- 2001-12-06 ES ES01992018T patent/ES2260323T3/es not_active Expired - Lifetime
- 2001-12-06 EP EP01990852A patent/EP1339715A2/en not_active Withdrawn
- 2001-12-06 SK SK710-2003A patent/SK287264B6/sk not_active IP Right Cessation
- 2001-12-06 EP EP01992018A patent/EP1343784B1/en not_active Expired - Lifetime
- 2001-12-06 CZ CZ20031563A patent/CZ20031563A3/cs unknown
- 2001-12-06 AU AU2002232482A patent/AU2002232482B2/en not_active Ceased
- 2001-12-06 DE DE60117859T patent/DE60117859T2/de not_active Expired - Fee Related
- 2001-12-06 EE EEP200300275A patent/EE200300275A/xx unknown
- 2001-12-06 DK DK01992018T patent/DK1343784T3/da active
- 2001-12-06 AU AU3248202A patent/AU3248202A/xx active Pending
- 2001-12-06 RU RU2003116060/04A patent/RU2302418C2/ru active
- 2001-12-06 PL PL01366115A patent/PL366115A1/xx not_active Application Discontinuation
- 2001-12-06 EE EEP200300272A patent/EE200300272A/xx unknown
- 2001-12-06 KR KR10-2003-7007535A patent/KR20040028690A/ko not_active Withdrawn
- 2001-12-06 US US10/013,060 patent/US6656938B2/en not_active Expired - Fee Related
- 2001-12-06 RU RU2003116061/04A patent/RU2315049C2/ru not_active IP Right Cessation
- 2001-12-06 NZ NZ526106A patent/NZ526106A/en not_active IP Right Cessation
- 2001-12-06 SK SK713-2003A patent/SK287732B6/sk not_active IP Right Cessation
- 2001-12-06 HR HR20030466A patent/HRP20030466A2/hr not_active Application Discontinuation
- 2001-12-06 AU AU2002239517A patent/AU2002239517B2/en not_active Ceased
- 2001-12-06 PL PL01365883A patent/PL365883A1/xx not_active Application Discontinuation
- 2001-12-06 AU AU3953002A patent/AU3953002A/xx active Pending
- 2001-12-06 KR KR10-2003-7007532A patent/KR20040023576A/ko not_active Withdrawn
- 2001-12-06 KR KR10-2003-7007539A patent/KR20040047733A/ko not_active Withdrawn
- 2001-12-06 AU AU3951602A patent/AU3951602A/xx active Pending
- 2001-12-06 RU RU2003116649/04A patent/RU2351598C2/ru not_active IP Right Cessation
- 2001-12-06 EE EEP200300270A patent/EE200300270A/xx unknown
- 2001-12-06 CN CNB018201598A patent/CN1247575C/zh not_active Expired - Fee Related
- 2001-12-06 KR KR10-2003-7007537A patent/KR20030070050A/ko not_active Withdrawn
- 2001-12-06 AU AU3951702A patent/AU3951702A/xx active Pending
- 2001-12-06 CA CA2436846A patent/CA2436846C/en not_active Expired - Fee Related
- 2001-12-06 IL IL15604401A patent/IL156044A0/xx unknown
- 2001-12-06 JP JP2002547930A patent/JP2004515501A/ja active Pending
- 2001-12-06 IL IL15604301A patent/IL156043A0/xx unknown
- 2001-12-06 CZ CZ20031592A patent/CZ303462B6/cs not_active IP Right Cessation
- 2001-12-06 CA CA002430844A patent/CA2430844A1/en not_active Withdrawn
- 2001-12-06 SI SI200130720T patent/SI1341790T1/sl unknown
- 2001-12-06 AU AU3061802A patent/AU3061802A/xx active Pending
- 2001-12-06 WO PCT/US2001/046697 patent/WO2002046192A2/en not_active Ceased
- 2001-12-06 CA CA002431151A patent/CA2431151A1/en not_active Withdrawn
- 2001-12-06 BR BRPI0116464-3A patent/BR0116464A/pt not_active IP Right Cessation
- 2001-12-06 DE DE60126645T patent/DE60126645T2/de not_active Expired - Fee Related
- 2001-12-06 CZ CZ20031562A patent/CZ20031562A3/cs unknown
- 2001-12-06 AT AT01987283T patent/ATE353895T1/de not_active IP Right Cessation
- 2001-12-06 SK SK711-2003A patent/SK7112003A3/sk unknown
- 2001-12-06 ES ES01987283T patent/ES2281456T3/es not_active Expired - Lifetime
- 2001-12-06 RU RU2003116063/04A patent/RU2003116063A/ru not_active Application Discontinuation
- 2001-12-06 MX MXPA03004974A patent/MXPA03004974A/es active IP Right Grant
- 2001-12-06 HU HU0400704A patent/HUP0400704A2/hu unknown
- 2001-12-06 MX MXPA03004972A patent/MXPA03004972A/es active IP Right Grant
- 2001-12-06 KR KR10-2003-7007538A patent/KR20040028691A/ko not_active Withdrawn
- 2001-12-06 EP EP01992005A patent/EP1341792A2/en not_active Withdrawn
- 2001-12-06 AT AT01992018T patent/ATE319711T1/de not_active IP Right Cessation
- 2001-12-06 PL PL01361948A patent/PL361948A1/xx not_active Application Discontinuation
- 2001-12-06 MX MXPA03004973A patent/MXPA03004973A/es not_active Application Discontinuation
- 2001-12-06 CZ CZ20031591A patent/CZ20031591A3/cs unknown
- 2001-12-06 WO PCT/US2001/046582 patent/WO2002046190A2/en not_active Ceased
- 2001-12-06 NZ NZ526089A patent/NZ526089A/en unknown
- 2001-12-06 CA CA002436983A patent/CA2436983A1/en not_active Abandoned
- 2001-12-06 SK SK684-2003A patent/SK6842003A3/sk not_active Application Discontinuation
- 2001-12-06 WO PCT/US2001/046696 patent/WO2002046191A2/en not_active Ceased
- 2001-12-06 AU AU2002239516A patent/AU2002239516B2/en not_active Ceased
- 2001-12-06 NZ NZ526086A patent/NZ526086A/en unknown
- 2001-12-06 HR HR20030467A patent/HRP20030467B1/xx not_active IP Right Cessation
- 2001-12-06 BR BRPI0116032-0A patent/BR0116032A/pt not_active IP Right Cessation
- 2001-12-06 AU AU2002232497A patent/AU2002232497B2/en not_active Ceased
- 2001-12-06 BR BR0116026-5A patent/BR0116026A/pt not_active IP Right Cessation
- 2001-12-06 EE EEP200300271A patent/EE200300271A/xx unknown
- 2001-12-07 TW TW090130404A patent/TWI293300B/zh active
- 2001-12-07 TW TW090130401A patent/TW584633B/zh not_active IP Right Cessation
- 2001-12-07 TW TW090130402A patent/TWI222972B/zh active
- 2001-12-10 AR ARP010105727A patent/AR035665A1/es unknown
- 2001-12-10 AR ARP010105726A patent/AR035664A1/es active IP Right Grant
- 2001-12-10 AR ARP010105729A patent/AR035667A1/es unknown
- 2001-12-10 AR ARP010105728A patent/AR035666A1/es unknown
- 2001-12-10 AR ARP010105731A patent/AR035669A1/es unknown
- 2001-12-10 AR ARP010105730A patent/AR035668A1/es unknown
-
2003
- 2003-05-28 NO NO20032452A patent/NO20032452L/no not_active Application Discontinuation
- 2003-05-28 NO NO20032449A patent/NO20032449L/no not_active Application Discontinuation
- 2003-05-28 NO NO20032451A patent/NO20032451L/no not_active Application Discontinuation
- 2003-05-30 NO NO20032473A patent/NO326159B1/no not_active IP Right Cessation
- 2003-06-06 NO NO20032595A patent/NO20032595L/no not_active Application Discontinuation
- 2003-06-06 NO NO20032596A patent/NO20032596L/no not_active Application Discontinuation
- 2003-07-08 ZA ZA200305273A patent/ZA200305273B/en unknown
- 2003-07-08 ZA ZA200305274A patent/ZA200305274B/en unknown
- 2003-07-08 ZA ZA200305271A patent/ZA200305271B/en unknown
- 2003-07-08 ZA ZA2003/05272A patent/ZA200305272B/en unknown
- 2003-07-08 ZA ZA200305275A patent/ZA200305275B/en unknown
- 2003-07-08 ZA ZA200305270A patent/ZA200305270B/en unknown
- 2003-10-07 US US10/680,989 patent/US7049439B2/en not_active Expired - Fee Related
- 2003-10-29 US US10/696,753 patent/US6953804B2/en not_active Expired - Fee Related
- 2003-10-29 US US10/696,476 patent/US20040092545A1/en not_active Abandoned
-
2005
- 2005-02-28 US US11/069,033 patent/US7132429B2/en not_active Expired - Fee Related
- 2005-05-19 US US11/132,900 patent/US7612083B2/en not_active Expired - Fee Related
- 2005-08-24 CY CY20051101024T patent/CY1105586T1/el unknown
-
2007
- 2007-05-09 CY CY20071100621T patent/CY1106569T1/el unknown
-
2009
- 2009-11-06 JP JP2009255040A patent/JP2010031040A/ja not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6670372B2 (en) | Aryl ether substituted imidazoquinolines | |
| US6677348B2 (en) | Aryl ether substituted imidazoquinolines | |
| AU2002239516A1 (en) | Aryl ether substituted imidazoquinolines | |
| US6664260B2 (en) | Heterocyclic ether substituted imidazoquinolines | |
| US20040157874A1 (en) | Amido ether substituted imidazoquinolines | |
| US20040102471A1 (en) | Thioether substituted imidazoquinolines | |
| AU2002232482A1 (en) | Amido ether substituted imidazoquinolines | |
| SK17972001A3 (sk) | Imidazochinolíny substituované močovinou | |
| AU2002232497A1 (en) | Urea substituted imidazoquinoline ethers | |
| AU2002230618A1 (en) | Heterocyclic ether substituted imidazoquinolines | |
| HK1072937A (en) | Thioether substituted imidazoquinolines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC9A | Refused patent application |